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Abstract 
 
Oct-4 is a POU-V domain transcription factor which regulates pluripotency in mammals 
and expressed in ES cells and germ cells, and was believed to be a gene unique to 
mammals. Recently, it has been demonstrated to be present in the genomes of Xenopus, 
zebrafish, sturgeon and axolotl. It has been shown that Oct-4 has three transactivation 
domains, (N), POU and (C), with DNA binding mediated through the POU domain. It 
was unknown how the activity of these domains has been retained through evolution 
and how they collectively function to control pluripotency.  
This study is new and is the first to analyse the functional conservation of these Oct-4 
homologues, and their regulation molecular. Three different assays were developed to 
study Oct4 functionality: 1) A transactivation assay in which the function of Oct4 
protein over-expression on a known Oct4-target sequence was assessed (by luciferase 
assay using the p6Wtk-luc reporter containing Oct4 binding sites); 2) A heterologous 
transactivation assay in which the function of specific Oct4 domains by linking them to 
Gal4-DNA binding domain was specifically assessed (DBD) (by luciferase assay using 
the pGal4-lux reporter). 3) The subcellular localization of Oct-4 homologues 
(generating two constructs; either full’ length or POU domain, fused to Green 
fluorescent protein (GFP). 
This study showed the coexistence of DBD conflicts with Oct4 resulting in a decrease 
on its transactivation capacity when compared to their native state. 
Oct-4 function generally conserved among species, with Xenopus Oct91 being the Oct-4 
homologue with a transactivation function more similar to mouse Oct-4.  Between (C) 
and (N) transactivation domains linked to DBD, the (C) domain was the one with more 
activity. The (C) domain is cell-type specific regulated by phosphorylation events, while 
the (N) domain suffers sumoylation. These two regulatory mechanisms are shared in all 
Oct-4 homologues. It was also possible to conclude that Oct-4 protein is nuclei 
transcribed. This project opens many possible studies in Oct-4 regulation. 
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(C) Carboxyl- terminal domain 
(N) Amino- terminal domain 
µg Microgram (10-6 g) 
aa Amino acid 
axC Axolotl Oct-4 C domain 
axN Axolotl Oct-4 N domain 
axOct4 Axolotl Oct-4 
Bp Base pairs 
BSA Bovine Serum Albumin 
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DMEM Dulbecco’s modified eagles medium 
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FFT Fast Fourier Transform 
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 g Gram, unit of mass 
GFP Green fluorescent protein 
HEK 293T Human Embryonic Kidney 293T 
hESc Human embryonic stem cells 
ICM Inner cell mass 
L Liter, unit of volume 
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M Molar 
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MCS Multiple cloning site 
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Xl60 Xenopus Oct-60 
Xl91 Xenopus Oct-91 
zfC Zebrafish pou2 C domain 
zfN Zebrafish pou2 N domain 
Zfpou2 Zebrafish POU2 
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Chapter 1: Introduction and literature review 
 
1.1 Overview 
Biologists have explored embryonic development, from worms to humans, to 
understand how different complex organisms can be derived from a single cell, the 
fertilised egg or zygote [1). It has been demonstrated that many conserved genes and 
pathways are involved in regulating development. The same genes have been linked to 
the same cell choices through evolution from simple to complex organism development. 
We also have a good understanding of the way that the embryo repeatedly uses the same 
strategies for organogenesis, tissue patterning and cellular specialisation [2]. All species 
use a common strategy for development, the use of a stem cell to generate and maintain 
a given tissue or organ.  During embryogenesis, cells are initially proliferative and 
pluripotent; with the ability to differentiate into any cell type; they only gradually 
become restricted to different cell fates [1, 2]. It is of interest to study if gene 
functionality is also conserved during evolution, and because the manipulation of these 
genes and pathways may hold the key to curing all known human disorders 
 
1.2 Pluripotency 
Pluripotent cells can give rise to all cells of the embryo or the adult organism [3]. In 
higher vertebrates Pluripotent cells express Oct-4, Nanog and Sox-2, and these factors 
are used as pluripotency markers. The potential that pluripotent cells have to develop 
into specialized cells is being researched for cell and tissue replacement therapies in 
order to treat disorders such as Parkinson’s disease, rheumatoid arthritis, burns and 
heart disease [1, 4]. Despite the fact that human embryonic stem cells (hESc) might be 
used to treat a host of diseases, there are ethical issues regarding the use of human 
embryos, as well as the problem of tissue rejection followed transplantation [5]. To 
bypass these issues, there is the possibility of reverting somatic patient cells into 
pluripotent cells by the constant forced over-expression of pluripotency factors [5]. So 
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far the process of reversion to a pluripotent phenotype is not very well understood 
however this technology holds much promise for regenerative medicine [6]. 
 The demonstration that fully differentiated cells can revert to pluripotency cell, has 
resulted in a longer number of groups interested in the process and the different 
pathways involved [6]. Pluripotent cells can be found in two main embryonic sources. 
Mouse and human ES cells are derived directly from the inner cell mass (ICM) of 
embryos at the pre-implantation stage [1] (Figure 1. 1-. Primordial gem cells (PGCs) 
produce mature germ cells and generate functional adult gametes. Mouse PGCs can be 
isolated from the gonadal ridge of the embryo [1, 7], and when cultured with 
appropriate factors in vitro, can generate embryonic germ (EG) cells [8]. EG cells have 
many characteristics of ES cells with respect to their differentiation potential [1], and 
therefore represent an alternative way to study genes that regulate potency and cell 
differentiation.  
 
 
Figure 1. 1- Different paths of establish pluripotent embryonic stem (ES) and 
embryonic germ (EG) cell lines from the inner cell mass (ICM) of mouse blastocysts 
and from primordial germ cells, respectively [7].  
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There are several methods to re-program the nuclei of differentiated cells to an ES cell-
like state (Table 1.1) for therapeutic means [9]. But none of these pathways are fully 
understood, and they still have many restrictions.  
 
Table 1.1- Different strategies for reprogramming differentiated cells into a 
pluripotent state [9]. 
Strategies for reprogramming of differentiated cells 
Reprogramming 
method 
Description Restrictions 
Somatic cell nuclear 
transplantation 
Introduction of a somatic cell 
nucleus into an enucleated 
unfertilised oocyte. For an 
increasing number of species, a 
complete organism can thus be 
formed by the reconstituted 
oocyte. 
Application may be limited 
by availability of oocytes 
and the low cloning 
efficiency. Furthermore, 
several developmental 
abnormalities were 
observed in cloned 
animals. Ethical and legal 
obstacles restrict use of this 
method for human cells. 
Cell-cell fusion Hybrids of differentiated and 
pluripotent cells exhibit 
characteristics of pluripotency. 
The reprogrammed cell 
hybrids contain an 
additional set of 
chromosomes. The nucleus 
of the pluripotent cell may 
be required for 
reprogramming. 
Treatment with extracts 
of pluripotent cells 
Permeabilised cells are 
exposed to cell-free extracts of 
pluripotent cells. Treated cells 
re-express pluripotency 
markers and re-differentiate 
into multiple lineages. 
Limited experience with 
primary cells. 
Reprogrammed cells will 
regain only some of the 
properties of pluripotent 
cells. 
Stable expression of 
defined factors 
Exogenous expression of Sox2, 
Oct3/4, Kif4, and c-Myc and 
subsequent selection for 
pluripotency markers gives rise 
to cells with similarity to 
pluripotent cells. 
Reprogrammed cells can 
contribute to tissues of all three 
germ layers in live chimeric 
mice 
Reactivation of transgenes, 
in particular of the 
oncogene c-Myc, leads to 
considerable side effects in 
offspring oh chimeric mice. 
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A major breakthrough was made by Takahashi and Yamanaka (2006), who induced 
pluripotency by retroviral transduction of differentiated cells using four transcription 
factors: Oct-3/4, Sox-2, c-Myc, and Klf-4 [3, 10]. Later in 2007, Thompson’s team 
screened genes that were highly expressed in hES cells, and found c-Myc and Klf-4 
necessary for reprogramming. They were also able to reprogram somatic cells using 
Oct-4, Sox-2, Nanog, and Lin-28 using lentiviral transduction [10, 11]. In all cases, the 
re-programmed cells contribute to live chimeric mice and are transmitted via the 
germline [3]. Although differentiation of cells involves complex genetic and epigenetic 
changes [3], it is not known how each transcription factor interacts and contributes to 
pluripotency.  
 
1.3 Research in lower vertebrates 
 
During evolution, most genes have undergone epigenetic modifications. Pluripotent 
genes are responsible for regulating the differentiation capacity of a cell, and it is likely 
that these genes might be found conserved during evolution, with small or no epigenetic 
modifications. In order to understand how pluripotency is regulated, it is easier to study 
a basic model organism, where the interference of a complex gene network does not 
occur.  
Mammalian systems have a more complex genetic network than amphibians, and 
mammalian oocytes are also harder to work and have many legal and ethical problems. 
For this reason Xenopus oocytes started to be used to do research on reprogramming by 
using their germ cell factors [5]. It is also easier to do experiments in Xenopus oocytes 
of than mouse oocytes, as mouse oocytes recover poorly after injection. Both systems 
have the formation of PGC, and the same genes that are found expressed in inner cell 
mass (ICM) can also be found in PGC. There are two different ways of generating 
PCGs. 
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The germline is created by primordial germ cell (PGC) formation, which may either be 
initiated by cell-autonomous maternal determinants [12] produced during oogenesis 
(termed germ plasm), this method is called preformation [13]; or by inductive external 
signals in the absence of germplasm, termed epigenesis [2].  
Frogs, such as Xenopus laevis, have germplasm [14], which is seen as dense 
fibrogranular bodies present in the cytoplasm of oocytes located in the cortex region of 
the oocyte [13]. During early development there is the inheritance of these maternal 
determinants [15] leading to the formation of primordial germ cells (PGCs) [13]. By 
contrast, mammals use Wnt and FGF signalling as key regulators in the inductive 
methods of PGC formation which takes place later in embryogenesis. The axolotl 
(Mexican salamander), is actively being used to study PGC development by the 
Johnson laboratory, due to the fact that mouse and axolotl appear to share the same 
inductive mechanism. Axolotl germ cells are induced in mesodermal tissues during 
gastrulation, by a very similar process to that of mouse germline formation [14, 15]. 
This finding brought a new insight in research, not only do they share the same 
development process but they also have the advantages of amphibian oocytes.  
The two different mechanisms of PGC formation is hypothesised to have lead to the 
appearance of two major amphibian groups; the anurans (frogs and toads), and the 
urodeles (salamanders) [14]. When the adult morphology of frogs (anuran) or axolotls 
(urodele) are compared to other vertebrates it is seen that urodeles have a similar 
skeletal structure to most vertebrates them frogs [14]. More morphological analyses 
between those two species also show that the frog’s anatomy has become more 
specialised, with significant variability among species than axolotls.  Frogs also go 
through many development stages that are not necessary for mammals [14]. Despite the 
fact that axolotl and frogs diverged from a common ancestor [12], axolotls retained 
more ancestral features and are less variable than frogs, and therefore is likely that one 
of the mechanisms of PGC specification in urodeles is more conserved than in frogs 
[14]. A strong link can therefore be drawn between animals that make PGCs by 
maternal determinants to allow more rapid speciation and evolution (frogs), and animals 
that epigenetically specify PGCs which are slower to speciate and evolve (axolotl and 
mouse). 
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It was assumed that as germplasm determines the formation of PGCs via coding and 
non-coding maternal RNAs, such as vasa, dazl genes [12, 15] that these would not be 
present or expressed in animals showing epigenetic PGC formation, but this was 
contradicted in 2001, when Johnson et al were able to clone the dazl sequence from 
axolotls. 
 Oct-4 has been shown to be essential for germ cell development in mammals [12] and 
is responsible for maintaining the ability of a cell to differentiate into all cell type; in the 
mammalian germ-line, and it was thought that Oct-4 was an evolutionary gene restricted 
to mammalian systems. However, in 1992, three homologous Oct-4 (family termed 
POU-V) sequences were isolated in Xenopus laevis; Oct-25 (Xl25), Oct-91 (Xl91) and 
Oct-60 (Xl60) [16]. In 2006, a homologous sequence was found in Zebrafish, Pou2 
(zfpou2) [17]. Later, the Johnson Group cloned Oct-4 from axolotls (axOct4) [18], and 
more recently, in sturgeon (stOct4) (unpublished). The presence of Oct-4 in species that 
specify PGCs by epigenesis and by preformation suggest that Oct-4 not only is an 
ancient gene, has but also has an important role in both types of PGC formation.  
Other genes, such as the well characterised transcription factors Oct-4, Nanog, c-
Myc,Sox2 between others, show a significant role in PGC determination, and are also 
found in lower vertebrates during early development. It is of interest that when vasa, 
dazl and Oct-4 from axolotl, Xenopus and mouse are aligned the axolotl sequence 
shows more similarity to mouse than Xenopus sequence [12]. It is likely that in 
urodeles, like in mammals, RNA binding proteins (vasa and dazl) and the transcription 
factor Oct-4, might control the formation of PGC and retain the potency for self renewal 
[15].   
Despite species having different modes of embryonic development, they all conserve 
the same inductive ancestral genes for PGC formation, whether by epigenesis or by 
preformation. However, it remains to be tested if their function was also conserved 
during evolution. The fact that axolotl sequences share a higher homology with mice 
suggest that they may be a good model organism for studying and understanding the 
biology of mammalian germ cell development, and the regulatory mechanism to 
produce stem cells. Gathering all the amphibian advantages, new insights might be 
gained into Oct-4 function through experiments in axolotls instead of Xenopus. 
Introduction and literature review 
7 
 
 
1.4 Oct-4 belongs to POU transcription factor family 
 
The POU family of transcription factors share homology to a domain first found in 
mammalian transcription factors Pit-1, Oct-1 and a nematode regulatory protein, Unc-86 
[23]. POU family transcription factors activate expression of genes by binding to an 
octameric sequence [AGTC(A/T)AAT] found in the regulatory sequences of cell type-
specific as well as ubiquitous genes [1]. The POU domain binds to DNA through 
recognition of the helix-turn-helix region within the POU domain, with the bases in the 
DNA major groove at the 3’ A/TTTA rich portion of the octamer site [1].   
The POU family members share a similar DNA binding domain of approximately 160 
residues [19], and contain two structurally independent subdomains, an amino-terminal 
specific region of 75-amino-acids (POUs) and a carboxy-terminal homeodomain of 60 
amino-acids (POUH) [20] connected by a flexible linker of variable length [1]. The POU 
domain was highly conserved during evolution – the mouse Oct-4 POU domain shares 
high similarity with amphibian sequences. It has been shown that the Xenopus Oct-4 
homologues can replace the mouse POU domain in ES cells to support their self-
renewal; zebrafish pou2 is unable to do this [21]. This suggests that the Oct-4 
transactivation function has been preserved in some species during evolution.  
POU transcription factors are divided into five classes based on the degree of 
conservation within these domains and linker region [21].The POU-V family are 
considered to play an important role during embryogenesis, pattern formation and 
cellular differentiation [22]. Oct-4 is also known as Oct3, Oct-3/4, POU5F1, OTF3, and 
NF-A3 [23].   
Oct-4 is transported to the nucleus, where it binds the octamer motif and starts to 
transactivate its target genes [24]. The mechanism by which Oct-4 is transported into 
the nucleus is still unknown, but a conserved sequence necessary for nuclear 
transportation has been found [24]. The classical nuclear localization signal (NLS) 
RKRKR was also found within the POU domain [24). 
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1.5 Oct-4 domains 
 
The POU domain in Oct-4 is surrounded by N- and C- terminal domains that are 
responsible for the transactivation capacity [1, 15]. Despite both functioning as 
transactivator domains, the C-terminal (C) shows less activity then the N- terminal (N) 
when tested in ES cells [16]; however, this has not been tested in other cell types, or by 
using Oct-4 homologues from other species. The (N), POU and (C) domains by 
themselves are not sufficient for ES cell self-renewal [16, 21]. 
The (N) domain is found upstream from the POU domain, and in mouse is 126 aa [21]. 
Oct-4 like proteins in other species have longer N-domains (e.g. 252 aa for Zebrafish 
Pou2). Due to the fact that 25% of the domain is proline (13- 60 aa) it is considered a 
proline-rich transactivation domain [16]. It was shown that the proline-rich region has 
an important role on Oct-4 transactivation, as when deleted Oct-4 transactivation is 
reduced [21]. Further studies revealed that deletion of the full N-domain decreases Oct-
4 transactivation. Nonetheless, it was still possible to see a significant transcriptional 
function in ES cells [16]. Mouse (N) domain has a target site for a small ubiquitin-
related modifier (SUMO-1) that results in a significant increase of Oct-4 stability and 
DNA binding [23].  However, if these sumoylation sites are conserved and influence 
Oct-4 homologues activity, is still not known. 
The (C)- domain is found downstream of the POU domain, and in mouse it contains 67 
to 95 aa. It has proline, serine and threonine residues [20] and is known as a 
serine/threonine-rich transactivation domain [16]. The C-domain is cell-type-specific 
and is mediated by the Oct-4 POU domain [20]. It is believed that (C) might be 
regulated by phosphorylation events [15, 20].  
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1.6 Oct-4 and pluripotency 
It was shown that in the absence of Oct-4, ES cells lose the ability to self-renew (Niwa, 
2002). Oct-4 is not the only gene responsible for maintaining pluripotency - other genes 
act together at different development stages (Figure 1. 2). In mouse, Oct-4 
transactivation is also mediated by directly binding Sox2, a Sry/HMG transcription 
factor [15, 25]. Oct-4/ Sox-2 co-operate to up-regulate genes during pre-implantation 
development, such as FGF-4 and osteopontin (OPN), and down-regulate human 
chorionic gonadotropin (HCG) [15].   
Nanog, another critical transcription factor that promotes ES self-renewal, was found by 
Chambers et al. (2003) [26] and Mitsui et a.l (2003) [27]. Nanog is a divergent 
homeobox factor expressed in vivo during early development [1]. In vitro it is a marker 
of all pluripotent cell lines (both murine and human) [1, 27]. Nanog and Oct-4 work 
together in order to maintain a pluripotent phenotype. In mouse, it is known that Nanog 
and Oct-4 interact directly with each other in a transcriptional complex with chromatin 
modifiers (James Dixon, personal communication). It is not known whether the ability 
to bind Nanog is common to all Oct-4 proteins. Nanog regulates Oct-4 and Sox2 levels 
to preserve self-renewal and to prevent differentiation of the ICM into all three germ 
layers [28]. 
 
 
Figure 1. 2 Model of Oct4, Nanog, Sox2, and FoxD3 interaction during early mouse 
development [1]. 
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Oct4- has been proven to be a transcription factor necessary to maintain pluripotency in 
embryonic stem cells (ES cells) along with other transcriptional co-regulators, such as 
Nanog and Sox-2 [1,29],  but once cells start to differentiate, it is switched off. Oct-4 is 
not restricted to ES cells, but is also found in adult tissues, such as bone marrow, 
intestinal epithelium, brain, liver and hair follicles [29, 30]. To investigate whether Oct4 
is necessary for adult tissue renewal, Jaenish in 2007 deleted Oct-4 in differentiated cell 
lines, and showed that, despite lacking Oct-4 cells where able to renew. This study 
shows that Oct-4 does not play a self-renewal role in adult cells [29, 30], and highlights 
some new ideas and concepts. Despite the fact that Oct-4 has a role in maintaining ES 
pluripotency, it does not have the same role in adult cells and could mean that 
pluripotency and self-renewal have different regulatory mechanisms [30]. 
 
1.7 Oct4 expression 
 
In mouse Oct-4 is a maternally inherited transcription factor that is expressed at low 
levels in all blastomeres until the 4-cell stage. Afterwards, the gene undergoes zygotic 
activation, resulting in high Oct-4 protein levels in the nuclei of all blastomeres until 
their compaction [1, 15] (Figure 1. 3). After cavitation, Oct-4 is only expressed in the 
inner cells (ICM) of the blastocyst and it is downregulated in the differentiated 
trophectodrem (TE). It was thought to be one of the first transcription factors to be 
regulated in early development [15, 20]. But nowadays it is known that Oct-4 requires 
the interaction with other transactivation factors such as Sox-2, to maintain ES cells in a 
pluripotent state [25]. 
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Figure 1. 3- Oct-4 expression in pre-implantation and early post-implantation 
during mouse development. It begins to be present as maternal transcript in the zygote 
and remains low until the 8-cell stage when the gene is zygotically activated, eventually 
becoming restricted to the epiblast [15]. 
 
A study with different Oct-4 expression levels revealed that when Oct-4 expression is 
increased by 50%, it leads ES cells to differentiate into extra-embryonic endoderm and 
mesoderm. However, a 50% decrease result in trophoectoderm differentiation [31]. 
Nonetheless, subtle Oct-4 changes do not have a drastic effect. Xenopus has a similar 
expression regulation, when Oct-25 (Xl25), Oct-60 (Xl60) and Oct-91 (Xl91) are over-
expressed it suppresses mesoderm formation, while loss of Oct-25 and Oct-60 results in 
mesoderm differentiation [22]. Oct-4 cell-type specificity and temporal expression 
suggest unique mechanisms for regulating its expression [32], it is the precise threshold 
of Oct-4 that determines the three possible cell paths (self-renewal, trophectoderm, or 
extra-embryonic endoderm and mesoderm) [1]. 
 
1.8  Aims and Objectives 
 
Oct-4 passed from a mammalian specific transcription factor to a transcription factor 
present in at least five embryo vertebrates; mammals; axolotl [12]; sturgeon (not 
published); in zebrafish and Xenopus [21]. Oct-4 in mammals is responsible for 
maintaining pluripotency, and essential for the formation of PGCs. This gene is found 
conserved during evolution, and it is of interest to study if it retained the same function 
to activate Oct-4 target genes from mammals to lower vertebrates. 
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The aim of the present study was i) to see whether the Oct-4 proteins from different 
species share the same functional domain; ii) if their activity was conserved during 
evolution in differentiated and pluripotent cells; iii) to determine how domains influence 
Oct-4 transactivation in these cells; iv) create different molecular tools for Oct-4 genes 
to allow further functional analysis and vi) assess subcellular localization.  
This study will not only highlight different aspects of Oct-4 conservation and function, 
but it will also allow  determination which of lower vertebrate share the highest 
functional conservation to mammals and present an alternative model system to study 
pluripotency pathways. 
 
These aims were addressed by caring out  the following studies: 
 a) Determination of the different domains for all Oct-4 sequences; analyse their 
length, amino acid composition and conservation; 
 b) Cloning of the full length and Oct-4 domains into a general utility vector by 
PCR; 
 c) Sub-clone these into over-expression GFP and Gal4DBD vectors; 
 d) Assess Oct-4 localization. 
e) Analysis of the function of Oct-4 to activate target genes by reporter analysis; 
 f) Analysis of the regulation and conservation of particular Oct-4 domains for 
their  function. 
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Chapter 2: Material and Methods 
 
2.1. Construction of expression vectors and reporter plasmids. 
 
Oct-4 is divided in three different domains, an amino terminal domain (N-domain) 
which has a large proportion of proline residues, a carboxyl terminal domain (C-
domain), which has a large proportion of proline serine and threonine residues that 
surrounds the POU domain [16]. Different Oct-4 fragments were constructed for each 
species, the Oct4 full- length (FL), the N-terminal and POU domain (N-POU), the C 
terminal and POU domain (POU-C), and also fragments with only the N-domain (N), 
POUV domain (POU) or C-domain (C), all fragments are described on Figure 2. 1.  
 
 
Figure 2. 1- Different Oct-4 domain constructs. A) full length Oct-4 domain; B) N-
POU domain, that only has the N-terminal and POU domain; C) POU-C domain, only 
with the POU domain and C-terminal; D) POU domain, E) C domain, only the C-
terminal, F) N domain, only with the N-terminal. 
 
Oct-4 Sturgeon (stOct4) sequence was supplied by James Dixon. Axolotl (axOct4), 
mouse (mOct4), Xenopus (XL91, Xl60, Xl25) and Zebrafish (Pou2) Oct-4 sequences 
were obtained through NCBI database [33], (sequences and accession numbers are 
given in appendix 1 to 7).  
Brikman in “Conserved roles for Oct4 homologues in maintaining multipotency during 
early vertebrate development” [9], describes the domain lengths for mouse Oct-4, 
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Xenopus Oct-25, Xenopus Oct-91, Xenopus Oct-60 among others. This information was 
not only used for domain constructs, but also, to predict Pou2, stOct-4 and axOct-4 
domains by using ClustW multiple alignments on BioEdit v. 7.0.9 [34]. The resulting 
alignment is shown on Figure 2. 2.  
 
 
Figure 2. 2- ClustW amino acids alignments, (the lightened area determines the POU 
domain, the upstream region correspond to N-terminal domain (N) and the downstream 
region corresponds to the C-terminal domain (C).) 
 
The lengths of each domain to be used to PCR amplification are described in  
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Table 2. 1. 
 
 
 
 
 
Table 2. 1- Domain lengths of Oct4 in the studied samples. 
Specie Domain Length (bp) 
Axolotl Oct4 N domain 1-549  
 POU domain 550- 996  
 C domain 997- 1197  
Mouse Oct4 N domain 1-399  
 POU domain 400- 846  
 C domain 847- 1131  
Sturgeon Oct4 N domain 1- 705  
 POU domain 706- 1158  
 C domain 1159- 1362  
Zebrafish N domain 1- 756  
 POU domain 757- 1209  
 C domain 1210- 1419  
Xenopus 91 N domain 1- 660  
 POU domain 661- 1143  
 C domain 1144- 1338  
Xenopus 60 N domain 1- 612  
 POU domain 613- 1076  
 C domain 1077- 1281  
Xenopus 25 N domain 1- 690  
 POU domain 691- 1140  
 C domain 1141- 1347  
  
Each fragment was cloned using different restriction enzyme sites surrounding them. 
Using NEB cutter Ver.2.0 (35), it was possible to identify which enzymes that do not 
cut in each sequence, and ones that cut within the fragments. The main restriction 
enzymes chosen where; Nhe, AgeI, XhoI and HindIII and only when necessary replaced 
by, other restriction enzymes, Sal 1 and and BglII. Restriction enzyme sequences were 
added to the primer sequence.  
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Axolotl Oct4 has a restriction site at the 82 bp for the Xho1 (35), indicated on  Figure 2. 
3 with the symbol ( ), so only the fragment N-POU needs to be replaced by Sal1 to 
avoid double digestion. All enzyme combinations for each domain are indicated on 
Figure 2. 3 and constructs domain lengths for axOct4 are indicated in the Table 2. 2. 
 
Figure 2. 3- Enzymes used to create the different Axolotl Oct-4 fragments.  
indicates where the Xho1 cuts the sequence. 
 
Table 2. 2-- Axolotl Oct4 enzyme combinations used to generate different 
fragments. 
Specie Restriction Enzymes Domain Size (bp) 
Axolotl Oct4 Nhe1 + HindIII  Full- Length 1197 
 Age1 + HindIII  POU-C 648 
 Nhe1 + Sal1  N-POU 996 
 Nhe1+ Age1  N domain 549  
 Age1 + Xho1  POU domain 447  
 Xho1 + HindIII  C domain 201  
 
Mouse Oct4 has a restriction enzyme at the 105 bp for HindIII [35], indicated on Figure 
2-4 with the symbol ( ), so the only full- length fragment needs a replacement of the 
HindIII adaptor for BglII. All enzyme combinations and constructs used to make the 
different fragments are described on the Figure 2. 4, and the respective domain sizes can 
be found in Table 2. 3. 
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Figure 2. 4- Enzymes used to create the different Mouse Oct-4 fragments.   
indicates where the HindIII cuts the sequence. 
 
 
Table 2. 3- Mouse Oct4 enzyme combinations used to generate different fragments 
Specie Restriction Enzymes Domain Size (bp) 
Mouse Oct4 Nhe1 + BglII  Full Length 1131 
 Age1 + HindIII POU-C 732 
 Nhe1 + Xho1  N-POU 846 
 Nhe1+ Age1  N domain 399 
 Age1 + Xho1 POU domain 447 
 Xho1+ HindIII C domain 285 
 
Sturgeon Oct-4 has a restriction site at the 1024 bp for Xho1 [35], indicated on Figure 2. 
5 with the symbol ( ), therefore the fragments N-POU and POU cannot take the Xho1 
adapter, being replaced by Sal1. The enzyme combinations used to make the fragments 
are described in Table 2. 4. 
 
 
Figure 2. 5- Enzymes used to create the different Sturgeon Oct-4 fragments.   
indicates where the Xho1 cuts the sequence. 
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Table 2. 4- Sturgeon Oct4 enzyme combinations used to generate different 
fragments. 
Specie Restriction Enzymes Domain Size (bp) 
Sturgeon Oct4 Nhe1 + HindIII  Full Length 1362 
 Age1 + HindIII POU-C 657 
 Nhe1 + Sal1 N-POU 1158 
 Nhe1 + Age1  N domain 705 
 Age1 + Sal1 POU domain 453 
 Xho1+ HindIII C domain 204 
 
Zebrafish Pou2 and all Xenopus (Xl25, Xl60, Xl91) cDNA do not have restriction sites 
for any of the main enzymes (Nhe1, Age1, Xho1 and HindIII) [35] so all the fragments 
were inserted with the same adapters but generating different size fragments. The 
restriction enzymes sites are described on Figure 2-6, and all the different combinations 
and fragment sizes for zfPou2 are in the Table 2. 5, for Xl91 the fragments are described 
on Table 2. 6, for Xl60 the fragments are on  
Table 2. 7 and for Xl25 are in  
Table 2. 8. 
 
Figure 2. 6- Enzymes used to create the different Zebrafish Pou2, Xenopus Oct-91, 
Xenopus Oct-60 and Xenopus Oct-25. 
 
Table 2. 5- Zebrafish Pou2 enzyme combinations used to generate different 
fragments.  
Specie Restriction 
Enzymes 
Domain Size (bp) 
Zebrafish Nhe1 + HindIII  Full Length 1419 
 Age1 + HindIII  POU-C 663 
 Nhe1 + Xho1  N-POU 1209 
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 Nhe1+ Age1  N domain 756 
 Age1 + Xho1 POU domain 453 
 Xho1 + HindIII C domain 210 
 
 
 
 
 
Table 2. 6- Xenopus Oct-91 enzyme combinations used to generate different 
fragments.  
Specie Restriction 
Enzymes 
Domain Size (bp) 
Xenopus Oct-91 Nhe1 + HindIII  Full length 1338 
 Age1 + HindIII  POU-C 678 
 Nhe1 + Xho1  N_POU 1143 
 Nhe1+ Age1  N domain 660 
 Age1 + Xho1  POU domain 483 
 Xho1 + HindIII C domain 195 
 
 
Table 2. 7- Xenopus Oct-60 enzyme combinations used to generate different 
fragments..  
Specie Restriction 
Enzymes 
Domain Size (bp) 
Xenopus Oct-60 Nhe1 + HindIII  Full length 1281 
 Age1 + HindIII  POU-C 669 
 Nhe1 + Xho1  N-POU 1076 
 Nhe1+ Age1  N domain 612 
 Age1 + Xho1  POU domain 464 
 Xho1 + HindIII C domain 205 
 
 
Table 2. 8- Xenopus Oct-25 enzyme combinations used to generate different 
fragments.  
Specie Restriction Enzymes Domain Size (bp) 
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Xenopus Oct-25 Nhe1 + HindIII  Full length 1347 
 Age1 + HindIII  POU-C 657 
 Nhe1 + Xho1  N-POU 1140 
 Nhe1+ Age1  N domain 690 
 Age1 + Xho1  POU domain 450 
 Xho1 + HindIII C domain 207 
  
 
Each fragment was amplified with  primers corresponding to specific enzyme with the 
addition of a random nucleotide sequence: CAGT at the 5’ extremity of each primer. 
The enzymes and their corresponding sequences that were used are described in Table 
2.9. The total oligonucleotide sequence with the adaptor sequences are described in 
Table 2-10. 
 
Table 2. 9- Enzymes and adaptors used to create different Oct4 fragments for each 
species. 
Fragment Enzyme  Adaptors A M S Z 25 60 91 
FL Nhe1 F+ HindIII R 5’CAGTGCTAGC+ 5’CAGTAAGCTT + - + + + + + 
FL Nhe1 F+ BglII R 5’CAGTGCTAGC+ 5’ CAGTAGATCT - + - - - - - 
POU-C Age1 F+ HindIII R 5’CAGTACCGGT+ 5’CAGTAAGCTT + + + + + + + 
N-POU Nhe1 F+ Xho1 R 5’CAGTGCTAGC +5 CAGTCTCGAG - + - + + + + 
N-POU Nhe1 F+ Sal1 R 5’CAGTGCTAGC +5’CAGTGTCGAC + - + - - - - 
POU Age1 F+ Xho1 R 5’CAGTACCGGT+ 5’CAGTCTCGAG + + - + + + + 
POU Age1 F+ Sal1 R 5’CAGTACCGGT+5’CAGTGTCGAC - - + - - - - 
CD Xho1 F+ HindIIIR 5’CAGTCTCGAG+ 5’CAGTAAGCTT + + + + + + + 
ND Nhe1F + Age1 R 5’CAGTGCTAGC+ 5’CAGTACCGGT + + + + + + + 
Adaptors include the CAGT sequence plus the enzyme sequence. The boldface section corresponds to the 
enzyme sequence.  A- Axolotl, M- Mouse, S- Sturgeon, 25- Xenopus Oct25, 60- Xenopus Oct60, 91-
Xenopus Oct91. (+) where the combination was used (-) species without this combination 
 
 
.  
Table 2-10. Oligonucleotides used for creating Oct4 mutants 
MOUSE OCT4  
    MOCT4-NHE1-F1 5’CAGTGCTAGCATGGCTGGACACCTGGCTTCA 
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    MOCT4-AGE1-R1 5’CAGTACCGGTTTTCATGTCCTGGGACTCCTC 
    MOCT4-AGE1-F1 5’CAGTACCGGTGCCCTGCAGAAGGAGCTAGAAC 
    MOCT4-XHO1-R1 5’CAGTCTCGAGACTTGATCTTTTGCCCTTCTG 
    MOCT4-XHO1-F1 5’CAGTCTCGAGATTGAGTATTCCCAACGAGAA 
    MOCT4-BGLII-R1 5’CAGTAGATCTACCCCAAAGCTCCAGGTTCTC 
AXOLOTL OCT4  
    AXOCT4-NHE1-F1 5’CAGTGCTAGCATGGCTGGGCATTTGGGACAG 
    AXOCT4-AGE1-R1 5’CAGTACCGGTCCCTTCCTCGTCTCCGCTGTC 
    AXOCT4-AGE1-F1 5’CAGTACCGGTGGGACGTCGGCGGACCTTGAA 
    AXOCT4-SALI-R1 5’CAGTGTCGACGCTGCGCTTCCCCTTCTGTCG 
    AXOCT4-XHO1-F1 5’CAGTCTCGAGATTTGCCGGGAGGAGTATGAT 
    AXOCT4-HINDIII-R1 5’CAGTAAGCTTGTTGGAGTGCAGGTGCCTTCT 
STURGEON OCT4  
    STOCT4-NHE1-F1 5’CAGTGCTAGCATGTCTGATCGGTCTGTCACC 
    STOCT4-AGE1-R1 5’CAGTACCGGTATTCTCCTCTTCTTCCGAGTC 
    STOCT4-AGE1-F1 5’CAGTACCGGTTTGTCCACGGAGGAGCTGGAG 
    STOCT4-SALI-R1 5’CAGTGTCGACGGCCAGACGCTTCCCCTTCTG 
    STOCT4-XHO1-F1 5’CAGTCTCGAGCTGCCCTTTGATGAGGAGGGT 
    STOCT4-HINDIII-R1 5’CAGTAAGCTTGCTGGTCAGGTGTCCCAGCCC 
ZEBRAFISH OCT2  
    ZFOCT4-NHE1-F1 5’CAGTGCTAGCATGACGGAGAGAGCGCAGAGCCCA 
    ZFOCT4-AGE1-R1 5’CAGTACCGGTCAGAGTCTCCTCTTCCTCAGA 
    ZFOCT4-AGE1-F1 5’CAGTACCGGTACTACTGAAGATTTGGAGCAG 
    ZFOCT4-XHO1-R1 5’CAGTCTCGAGCAAAGCTAGACGCTTTCCCTT 
    ZFOCT4-XHO1-F1 5’CAGTCTCGAGCCCTTTGATGACGAGTGTGTT 
    ZFOCT4-HINDIII-R1 5’CAGTAAGCTTGCTGGTGAGATGACCCACCAA 
XENOPUS OCT91  
    XNOCT91-NHE1-F1 5’CAGTGCTAGC ATGTATAACCAACAGACCTACCCT 
    XLOCT91-AGE1-R1 5’CAGTACCGGT GGCTTCCTCCTCACTGTCACT 
    XLOCT91-AGE1-F1 5’CAGTACCGGTCCTAATTCTGGGGAGATGGAG 
    XLOCT91-XHO1-R1 5’CAGTCTCGAGCTCCCCGCCATTCTCCCTAAT 
    XLOCT91-XHO1-F1 5’CAGTCTCGAGCCTTATGACGCCCCCCAAACC 
    XLOCT91-HINDIII-R1 5’CAGTAAGCTTGTTGCCTTGGTTACCCATGCC 
XENOPUS OCT60  
    XLOCT60-NHE1-F1 5’CAGTGCTAG ATGGACCAGCCCATATTGTACAGC 
    XLOCT60-AGE1-R1 5’CAGT ACCGGTTCCATCCTCTTCAGTTCCAG 
    XLOCT60-AGE1-F1 5’CAGT ACCGGTATGACCCTTGAGGAGATGGAA 
    XLOCT60-XHO1-R1 5’CAGT CTCGAG TTGGACATTCTGAACTTGCTC 
    XLOCT60-XHO1-F1 5’CAGT CTCGAGGGGGCATGAGTTTGTGGGTGG 
    XLOCT60-HINDIII-R1 5’CAGT AAGCTTGCCGGTCAGGACCCCCATAGA 
XENOPUS OCT25  
    XLOCT25-NHE1-F1 5’CAGTGCTAGCATGTACAGCCAACAGCCCTTCCCA 
    XLOCT25-AGE1-R1 5’CAGTACCGGTGGGAACCTCCTCCTCATTGTC 
    XLOCT25-AGE1-F1 5’CAGTACCGGTAGCGAATCAGAAATGGAGCAG 
    XLOCT25-XHO1-R1 5’CAGTCTCGAGTCCCTGGCGCTTGCCTTTCTG 
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    XLOCT25-XHO1-F1 5’CAGTCTCGAGATGCCCACCGTTGAGGAGAAC 
    XLOCT25-HINDIII-R1 5’CAGTAAGCTTGCCAATGTGGCCCCCCATGGC 
XLOCT25-FULL LENGTH 
F1 
5’ATGTACAGCCAACAGCCCTTC 
    XLOCT25-FULL LENGTH 
R1 
5’TCAGCCAATGTGGCCCCCCAT 
 
The different fragments were generated by PCR from plasmids containing the cDNA 
templates of the genes to be amplified. This plasmids were supplied by James Dixon 
and Jodie Edgson. The amplification was done using the primers described above using 
REDTaq REadyMix (Sigma- Aldrich, UK) according to the manufacturer’s instructions. 
The amplification was performed on an Eppendorf Mastercycle epGradient S cycler 
machine. PCR reactions were heated to 94°C for 5 minutes followed by 45 cycles of 
denaturation at 94°C for 1 minute, annealing at 56°C for 5 1 minute and 30 seconds, and 
extension at 72°C for 1 minute and 30 seconds. After amplification the PCR samples 
were loaded on a (0.5X) TAE Agarose gel (1.2%) and separated at 135v. Their sizes 
where compared to 1kb and 100bp molecular weight markers (Biolabs, New England).  
After isolating the correct amplified size segments, they were purified from the gel 
using Qiaspin column and Gel Extraction Kits (QIAGEN, UK) according to the 
manufacturer’s instructions. 
PCR products were ligated into the pGEM®-T Easy vector (Promega, UK) according to 
the manufacturer’s instructions. The ligation mix was used to transform DH5-α E. coli 
competent cells. The culture cells were plated in LB agar medium supplemented with 
(10 mg/ml) Amplicilin and IPTG to 0.5mM and left to grow overnight at 37ºC. 
Individual colonies were selected and transfered to liquid LB medium with Amplicilin, 
overnight at 37ºC. 
Plasmid DNA was extracted from cultures using QIAprep Spin Miniprep Kit using a 
microcentrifuge (QIAGEN, UK). To confirm that the fragments were inserted into the 
pGEM®-T Easy vector, 5 µL of the miniprep DNA was digested with EcoRI 
(10000U/ml) (BioLabs, New England) for 1 hour and 30 minutes at 37ºC with 2µL of 
Buffer 2 (BioLabs, New England), 2 µL of 10X BSA, 2µL o EcoRI (BioLabs, New 
England) and 9µL of purified water. EcoRI cuts on either side of pGEM®-T Easy 
(appendix 12) vector at the 23 and 70 bp after the transcription site, it also cuts the 
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stOct-4 insert at 398 bp, due to an internal EcoRI site. When the fragments are correctly 
inserted into pGEM®-T  the fragment sizes described in the Table 2-11, should be 
obtained. 
 
 
 
Table 2-11- Size of the different fragments constructed of each species. 
Species Domain Size (bp) 
Axolotl Oct4 Full- Length 1197 
 POU-C 648 
 N-POU 996 
 N domain 549  
 POU domain 447  
 C domain 201  
   
Mouse Oct4 Full Length 1131 
 POU-C 732 
 N-POU 846 
 N domain 399 
 POU domain 447 
 C domain 285 
   
Sturgeon Oct4 Full Length 964 and 398 
 POU-C 657 
 N-POU 1158 
 N domain 398 and 310 
 POU domain 453 
 C domain 204 
   
Zebrafish Full Length 1419 
 POU-C 663 
 N-POU 1209 
 N domain 756 
 POU domain 453 
 C domain 210 
   
Xenopus 91 Full length 1338 
 POU-C 678 
 N_POU 1143 
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 N domain 660 
 POU domain 483 
 C domain 195 
   
Xenopus 60 Full length 1281 
 POU-C 669 
 N-POU 1076 
 N domain 612 
 POU domain 464 
 C domain 205 
   
Xenopus 25 Full length 1347 
 POU-C 657 
 N-POU 1140 
 N domain 690 
 POU domain 450 
 C domain 207 
  
The primary objective is to generate plasmids for the generation of fragments that can 
be ligated into specific vectors, pATG and pDBD, for transcriptional assays.  
 
 
2.1.2. pATG 
 
pATG vector is derived from pEGFP-C1 (Clontech) GenBank accession #: U55763. 
The vector and the alterations can be seen on Figure 2. 7. The Multiple cloning site 
(MCS) of pEGFP-C1 vector can be found in appendix 10. The MCS of pATG consists 
of Nhe1, Age1, Xho1, HindIII, BamHI (James Dixon, personal communication)  
 
 
Figure 2. 7- pATG vector used for cloning. 
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The enzymes in the pATG MCS are compatible with the fragments generated above. In 
order to clone the fragments into pATG, the vector and the fragments need to be 
digested with the respective enzymes that are described on Table 2. 2 and on  
Table 2. 8. To increase cloning efficiency pATG was also desphosphorylated by 
alkaline phosphatase, calf intestinal (CIP) (10,000 units/ml) (BioLabs, New England) 
after a double digestion with the restriction enzymes. 
Enzymatic digestion was performed using 300 ng/µL of plasmid, 3 µL of enzyme (1,5 
µl each), 3µL of BSA (10X) (BioLabs, New England) and 3µL of the respective buffer 
to a final volume of 30 µL. The buffers used for plasmid digestion were chosen using 
BioLab instructions [36]. Digestion was performed at 37ºC for 1h and 30 minutes.  
After digestion, the samples were loaded into a (0.5X) TAE 1.2% Agarose Gel and run 
at 135V. The correct fragments were identified by comparison to 1kb and 100bp 
molecular weight (MW) makers (BioLabs, NewEngland); extracted and purified using 
Qiaquick Spin- Gel Extraction Kit (QIAGEN, UK) according to manufacturer’s 
instructions. 
 
2.1.2.  pDBD 
 
pDBD- Gal4 vector was prepared by James Dixon (personal communication). It has the 
same similar MCS as pATG with the exception for Xho1which was replaced by Sal1 
(cohesive ends of Xho1 and Sal1) [36]. The vector can be seen in Figure 2. 8.  
 
 
Figure 2. 8- pDBD vector used for the cloning. 
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The vector was digested with the appropriate enzymes using the buffers suggested by 
BioLab instruction [36]. To create some of the vectors it necessary to do sequential 
digestion, due to the incompatible enzyme buffers [36]. The digestions were purified 
purified using Qiaquick Spin columns (QIAGEN, UK). Each digestion was done at 
37ºC for 1h and 30 min. After digestion, the samples and 1Kb and 100bp DNA ladder 
(BioLabs, New England) were loaded into TAE 1.2% Agarose Gel and fragments 
separated at 135V.  The correct fragments were extracted and purified using Qiaquick 
Spin- Gel Extraction Kit (QIAGEN, UK) according to manufacturer’s instructions. 
The ligation of fragments to vector was done to a ratio 5:1 in the presence of T4 DNA 
ligase (2000,000 units/mL) (BioLabs, New England) in appropriate buffer (BioLabs, 
New England). The reaction was performed at room temperature for 1h and 30 min. 
After ligation the mix was used to transform DH5α competent cells. The 
transformations were performed by adding 100µL of competent cells to the ligation 
reaction, and leaving on ice for 30 min. Then heatshock was performed at 42ºC for 45 
seconds followed by returning to ice for 3 minutes. 500µL of SOB is then added and the 
cells incubate in a 37ºC shaker for 1 hour and 30 minutes. After transformation, 200µL 
of the mixture is spread on an Agar (30µg/ml) plate and incubated overnight at 37ºC. 
Two distinct colonies are then picked and grown overnight in a 37ºC shaker, in liquid 
LB media supplemented with Kanamycin ((30µg/ml). Plasmid DNA is then extracted 
using Qiagen Plasmid Mini Kits (QUIAGEN, UK) according to manufacturer’s 
instructions.  
 
2.1.3. pGFP 
 
pGFP vector is identical to pDBD vector but instead of the DNA binding domain is has 
a green fluorescent protein (GFP) molecule, Figure 2. 9. The ligation and transformation 
were done in the same way as above described.  
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Figure 2. 9-Vector pGFP used in cloning. 
 
HeLa cells, were transfected with 0. 25µg/well of pGFP using GeneJuice Trasfection 
Reagent (Novagen, Germany) and incubated at 35ºC (5% CO2). Cells were fixed at 
room temperature for 25 min with 2% formaldehyde in phosphate buffered saline 
(PBS). Nuclei were stained with 4,′6-diamidino-2-phenylindole (DAPI)  and GFP expression 
was followed by fluorescence microscopy. 
 
2.2. Cell culture and transfection. 
 
HeLa cells and HEK 293T cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM; Sigma) supplemented with 10% fetal calf serum, 1X non-essential amino 
acids, and 100µg/ml antibiotics (penicillin and streptomycin). For reporter assays, 
approximately 200,000 HeLa and HEK 293T cells were seeded in 24-well cell culture 
plates and incubated at 37ºC (5% CO2) overnight. Cells should be 50-80% confluent 
before transfection. For the reporter assay  two different luciferase reporter were used. 
The reporter plasmid 6Wtk-luc (appendix 13) that was kindly provided by Dr. Niwa 
(16), and the Gal4-lux reporter. The plasmids were also co-transfected with pGL4.74 
(hRluc/TK) (Promega, UK). The transfection was done using GeneJuice Transfection 
Reagent (Novagen, Germany) according to manufacturer’s instructions. Cells were 
transfected with 0.25µg/well of the luciferase reporter DNA, and with 0.25µg/well of 
the test expression vector DNA and 0.05µg/well of the RL-TK DNA. Experiments were 
done in triplicates for each construct and reporter. The cells were left two days at 37ºC 
(5% CO2).  
The dual-luciferase assays were conducted by James Dixon. Dual luciferase assays were 
performed using a dual luciferase assay system (Promega, UK) in a Veritas™ 
Microplate Luminometer (P/N 9100-002) (Promega, UK).  Cells were lysed in 200ul 
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passive lysis buffer. For luminescence measurements, 25µl of firefly luciferase reagent 
(LARII) was added to 25µl of lysate sample, where the firefly luciferase activity is 
measured. Followed by addition of 25µl of stop and glow (the Renilla luciferase reagent 
and firefly quenching). The results are expressed as the ratio of firefly to Renilla 
luciferase activity, (Fluc/Rluc). Experiments were conducted in triplicate. 
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Chapter 3: Results 
 
3.1.  Oct4 domain structure. 
 
Oct-4 protein can be divided in three distinct functional domains; a POU domain which 
mediates DNA-binding function; an amino (N)-terminal (N), which has been shown to 
act as a ubiquitous transcriptional activation domain (TAD), and a carboxyl (C)-
terminal (C) as a cell-type specific TAD (16). The importance of these domains has so 
far been investigated using mouse Oct-4 (mOct4). So far no work has been carried out 
to determine the domain function of Oct-4 proteins in other species. Before, 
determining how the domains influence Oct-4 transactivation, and if that function is 
shared in similar Oct-4 proteins; it was necessary to localise the domains. 
As previously shown in Chapter 2, the domains have similar lengths, with the POU 
domain being the most conserved among all species. By using standard molecular 
biology techniques and mammalian over-expression analyses Oct-4 domain function 
through vertebrate evolution was investigated. To achieve this, vectors were created to 
express Oct-4 proteins by isolating and cloning different combinations of the N, POU 
and C domains. These fragments were isolated and recombined to form the constructs 
shown in Figure 2.1. The different vectors were used in different assays. 
 
3.2. Oct4 sequence identity as function prediction 
 
Apart from directly testing Oct-4 function experimentally, it is possible to predict how 
Oct-4 proteins might function by studying their amino acid sequence; domain 
conservation and sequences within them. As many Oct-4 studies have been conducted 
with mOct-4 and Xenopus Oct-4 (Xl91, Xl60, and Xl25) proteins, I aimed to predict 
protein behaviour by comparing the amino acid conservation and similarity of these two 
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species with axolotl (axOct-4), sturgeon (stOct-4), and zebrafish (zfPou2); it was also 
possible to determine the phylogenetic relationship between Oct-4 family members. 
This was practically examined by reporter analyses, which will be given later. 
 
The amino acid sequences of the Oct4 proteins were obtained using the cDNA 
sequences in Appendix 1 to 7, and afterwards were compared to previously published 
sequences in NCBI Genbank, except for stOct-4. The protein sequences where entered 
into BioEdit [34] to calculate the identity for the full length sequence, and also each 
domain individually. According to the values described inTable 3.1, axolot Oct4 has 
highest identity to mouse Oct4, when compared with all the species.  
Table 3. 1- Sequence identity of Oct4. 
Protein 
sequence 
A/M A/S A/Z A/25 A/60 A/91 M/S M/Z M/25 M/60 M/91 
Complete 0.263 0.234 0.224 0.253 0.256 0.249 0.232 0.195 0.222 0.222 0.219 
POU 0.469 0.483 0.032 0.273 0.435 0.417 0.423 0.022 0.106 0.376 0.410 
(C) 0.298 0.418 0.393 0.350 0.380 0.361 0.277 0.270 0.266 0.242 0.270 
(N)l 0.076 0.055 0.063 0.069 0.063 0.068 0.012 0.059 0.056 0.053 0.059 
The percentage was measured using BioEdit [34]. A corresponds to Axolotl; M to 
Mouse; S to Sturgeon; Z to Zebrafish Pou2; 25 to Xenopus Oct25; 60 to Xenopus Oct60; 
25 to Xenopus Oct25 
 
Protein 
sequence 
S/Z S/25 S/60 S/91 Z/25 Z/60 Z/91 25/60 25/91 60/91 
Complete 0.263 0.265 0.246 0.254 0.257 0.236 0.241 0.266 0.297 0.240 
POU  0.024 0.052 0.590 0.590 0.029 0.029 0.032 0.058 0.059 0.616 
(C) 0.581 0.373 0.411 0.380 0.319 0.360 0.356 0.342 0.443 0.376 
(N) 0.051 0.076 0.063 0.089 0.083 0.043 0.059 0.073 0.130 0.100 
The percentage was measured using BioEdit (34). A corresponds to Axolotl; M to 
Mouse; S to Sturgeon; Z to Zebrafish Pou2; 25 to Xenopus Oct25; 60 to Xenopus Oct60; 
25 to Xenopus Oct25 
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According to Table 3.1, Oct-4 mouse full length has more similarity with axOct4 
(0.263) that with any other species and the lowest identity is with Zebrafish Pou2 
(0.195). As expected, the POU domain is the most well conserved domain. Despite 
mouse and axolotl having a high level of similarity, it is not as high as sturgeon and 
zebrafish, but these two species came from the same ancestor (12). The identity starts to 
decrease drastically on the surrounding domains, (C) and (N), but even in those domains 
mouse and axolotl still share the highest similarity value. 
Using the full length amino acid sequence it is possible to draw a phylogenetic tree 
based upon average distance (Figure 3. 1).  
 
 
Figure 3. 1- Average distance tree using BLOSUM62 [34]. 
 
According to Figure 3.1 there is an evident division of the Xenopus Oct expression to all 
the others. Within the Xenopus, the Xl60 is closer to Xl25 than to Xl91. It also shows 
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that axOct4 and mOct4 share more similarities between them, that with any other 
species. StOct4 and zfpou2 also have a higher similarity between them. 
 
3.3.  Amino Acid Composition 
 
It is important to determine the amino acid composition, similarity between the different 
Oct-4 homologues. It is possible that a difference between and within the domains is 
based on their different amino acid composition. 
The amino acid composition of each species and the respective amino acid graphics can 
be found in Appendix 9 to 11. The amino acid composition was calculated using 
BioEdit program [34]. The full length values are not shown because it represents the 
sum of the domains.  
 
3.3.1  N- Terminal (N)- domain 
 
The N-domain was known by being a proline rich domain, due to the fact that 25% of 
its constitution is proline [16, 20], and that this amino acid plays an important role in 
mouse Oct-4 transactivation [16]. 
According to the amino acid composition predicted by BioEdit [34], mouse (N) does 
not have 25% of proline, but 14.29%, and also glycine is also the amino acid present in 
higher quantity (17.29%) followed by proline and then glutamic acid. In general, the 
proline values oscillate from 8.2% (axolotl) to 14.29% (mouse), the species with similar 
amount of proline to mouse is Xenopus Oct-25 followed by zebrafish. 
The amino acid found in higher quantity in axolotl and mouse is glycine; while in 
sturgeon, Xl91 and Xl60 is serine; in zebrafish Pou2 and in Xl25 is proline. Xenopus 
Oct-4 homologues (Xl25, Xl60, Xl91) have in common proline and serine constitution; 
and Xl60 is similar on the amount of glutamic acid when compared to mouse. 
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3.3.2  POU domain 
 
The values and respective graphics for POU amino acid composition are in Appendix 9. 
According to the results obtained, the amino acid present in higher amounts in axolotl, 
mouse, sturgeon, and zebrafish is leucine. In Xl91 and Xl25 is lysine while in Xl60 is 
glutamic acid. 
The second amino acid present in higher amount in axolotl is glutamic acid; in mouse is 
lysine; in sturgeon and zebrafish are lysine and arginine; in Xl91 is glutamine; in Xl60 
is lysine and leucine; and in Xl25 is leucine, glutamine and arginine. 
 
3.3.3  C- Terminal (C)-domain 
 
The amounts of amino acid present on the C-terminal can be found in Appendix 11. 
C-domain is known for having high amounts of proline, serine and threonine [16], but 
according to Table 3.4, proline is in fact present in significant levels, but not serine and 
threonine, the amino acids that are present in higher amounts are leucine and proline 
(13.68% and 12.63%). Proline is in fact present in high levels in stOct4 (16.18%), 
zbpou2 (20.00%), Xl91 (20%) and Xl60 (16.18%). In this same species, the second 
amino acid present in higher levels is glycine, fact also shared with Xl25.  
The tryptophan is the only amino acid present in mOct4 that is not present on the other 
species. In Nanog, the tryptophan is associated with the development of extra-
embryonic tissue (James Dixon, unpublished data).  
 
a)  Phosphorylation prediction 
 
If the C-terminal is correlated with phosphorylation events [40], tyrosine, serine and 
threonine are known to be involved in phosphorylation reactions. According to the table 
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on appendix 11, Xl60 is the one with more serine, but very low amounts of threonine 
and tyrosine. Axolotl (C) has big quantities of serine and tyrosine. The amino acid 
present in higher quantities in mOct4 is serine, but it also has threonine and tyrosine. All 
the other species also have the three amino acids related to phosphorylation. 
For phosphorylation events, the amino acid constitution is not enough, it is necessary a 
favourable composition of the surrounded amino acids. By using NetPhos 2.0 [38] it is 
possible to predict the probability of phosphorylation events to happen on a given 
sequence. The probability is scored from 0.5 to 1, only the values above 0.500 are 
considered. The results are shown in Table 3.2 and Table 3.3. 
 
Table 3. 2 Prediction of  phosphorylation positions in the C domain, for serine; and 
tyrosine, according to Netphos 2.0 [38]. 
Serine Tyrosine 
Position Sequence Score Position Sequence Score 
AxOct4 28 HLPTSYIAQ 0.930 6 CREEYDGFQ 0.670 
  56 SEMYSQTVS 0.735 55 DSEMYSQTV 0.653 
Moct4 5 EAPTSPHST 0.964       
  8 TSPHSTQSL 0.959       
  45 GDAVSQGKG 0.553       
StOct4             
Zbpou2       12 EAQYYEQSP 0.928 
XLOct25       12 DGEGYDVAQ 0.860 
        43 APQIYASAG 0.746 
XlOct60 26 XAVPSHGSG 0.829       
XlOct91 12 LTPPSQGPF 0.890       
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Table 3. 3 Prediction of  phosphorylation positions in the C domain, for serine; and 
tyrosine, according to Netphos 2.0 [38].  
Threonine 
Position Sequence Score 
AxOct4       
mOct4 34  PCIQTEAPA   0.768 
StOct4       
Zbpou2       
XLOct25 17 DVAQTMGRP 0.544 
XlOct60 7  IGLSTPQPS 0.561 
XlOct91 7 DAPQTLTPP 0.862 
 
According to Netphos 2.0 [38] stOct4 does not have relative phosphorylation sites, 
despite having threonine. Mouse C-terminal has four phosphorylation sites that might 
justify the hypothesis that this domain is regulated by phosphorylation events. 
Nonetheless, axC also has a high number of phosphorylation amino acids, two in serine 
and two in tyrosine. The Xenopus domains have less phosphorylation sites, but with a 
higher probability of occur. 
To know if those regions are conserved among the species in study, the sequence given 
by Netphosh (Table 3.2; Table 3.3) as phosphorylation place, were localized in a MAFT 
alignment and the phosphorylation sites where highlighted. The result can be seen in 
Figure 3.2.  
 
 
Figure 3. 2- C-Domain MAFT alignment with the phosphorylation sites 
highlightened; in blue is where it might be a phosphorylation in a serine amino acid; in 
red is where there might be phosphorylation in a threonine amino acid; in green is 
where phosphorylation might occur in a tyrosine amino acid. 
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Zebrafish Pou2, Xl91 and Xl25 have similar phosphorylation sites(10- 30 aa), and 
axolotl and mouse have a similar phosphorylation area (30 and 70 aa). 
 
3.4.  Alignments 
 
To study the conservation between the different species, it is necessary to make amino 
acid alignments. There are several alignment programs such as BioEdit [34]; Jalview 
[37]; Blast; Emboss:: Neddle; Emboss::Water. All of these have different algorithms for 
sequence alignment.  
MAFFT makes sequence alignments using a fast Fourier transform (FFT) 
approximation [39]. It is able to align more than 50 sequences with a higher accuracy 
than ClustalW [39], program that can be found in BioEdit. MAFFT version 5, can be 
found in Jalview v.2.3, that combined with Jalview tools display information about the 
quality conservation and consensus within the sequences [37]. The consensus display 
for the alignment is scored from 1 to 9, where 1 is the lower level, and when there is a 
100% match, it is scored with a (*). The consensus graphic combines all the sequences 
into the amino acid that is present in all sequences for the same position. For being more 
accurate, and for displaying more information in one data, the program used to make all 
sequence alignments was MAFFT from Jalview v.2.3.  The amino acid constitution 
from each sequence was also calculated by Jalview v2.3 [37]. 
 
3.4.1.  N-terminal (N)-domain 
 
The proline region of mOct4 is found between the 13-60 amino acid, and when that 
region is deleted there is a significant decrease in Oct-4 transactivation [16]. It was  
possible to see that the proline is not present in similar values for all species. However, 
it might be possible that proline is concentrated in the same area as mouse. The 
influence of this region on other species, is not known. 
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Figure 3. 3- N-terminal alignment for all species. The green delimitation shows 
where most of the proline is concentrated. The red delimitation shows a conserved area 
within the N-terminal. 
 
According to Figure 3.3, the proline region is not conserved within species, but there is 
a region where most of the proline can be found (160 to 180 aa). It is possible to see a 
different conserved area, where most of the amino acids are serine and glutamic acid, 
but this similarity is not shared in mouse sequence, now termed SEB Box. 
 
3.4.2.  POU-domain 
 
POU alignment can be seen in Figure 3.4. Duanquin Pei et at. (24) identified a nuclear 
localization signal (NLS) in mouse Oct-4. The NLS was found in the Pou domain, the 
sequence responsible for its localization in the nuclei and required for the 
transactivation of its target genes is RKRKR [24]. By comparing outa multiple 
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alignment of POU, it was possible to localise the sequence and find out if it is present 
and conserved for all species. 
 
 
Figure 3. 4- Jalview MAFFT alignments for the different POU domains, the 
selected area corresponds to NLS. 
 
Figure 3.4 shows how conserved the POU domain is among the different species. In most 
of the cases it has a 100% conservation and only one region with lower conservation (80 
and 90 aa). The NLS, in mOct4 with the sequence: RKRKR. However, in other species 
it was only found RKRK. It is not known if this sequence is enough to transport the 
Oct-4 sequence into the nucleus. The pGFP vector with different Oct-4 domain will 
help to determine whether the Oct-4 is transported into the nuclei or not. 
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3.4.3.  C-terminal (C)- domain 
 
The C-terminal MAFT alignment can be possible to see in Figure 3. 5. 
 
 
Figure 3. 5- MAFT multiple alignments for the different C-terminal sequences. 
 
The sequence is more conserved in the middle than in the domain extremities. In the 
middle (between 40- 70 aa) some of the phosphorylation amino acids are also found 
(Figure 3. 2). If this similarity is enough to regulate the cell type-specificity, in the same 
way as for mouse, it will be determine by over-expressed vectors, 
 
3.5. Cloning 
 
All full lengths and Oct-4 domains were successfully cloned into pGEM®-T Easy 
vector (Promega), with the exception of Xl25 that was not possible to isolate the correct 
band size by PCR. The band size was always 200 bp inferior to that expected; 
nevertheless this band was inserted into the vector and sent for sequencing. According 
to the sequencing the primer had a mismatch and this might be the reason why the band 
was always 200 bp smaller. 
Unfortunately, Due to time constraints, the subclonning of the full length and the 
domains into overexpression vectors was not completed in time for the Luciferase 
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assay. Therefore the assay was not done, nevertheless it was possible to do the assay 
pATG with the Oct-4 full length. 
The subclonning of the full length and the POU domain, was successfully done into 
pGFP vector, has well the subclonning of the full length into Gal4DBD vector. The (N) 
from zfpou2; POU from Xl91 and Xl60; (C) from mOct4, zfpou2 and Xl60 were not 
subcloned on time for the assay.  
 
 3.6. Nuclear localization  
 
It is important to determine whether Oct-4 protein is translocated to the nucleous. For 
that propose, the full length sequences and the POU domains were fused to a GFP 
signal, and that used for transfect 293T cells. The results can be seen in Figure 3. 6 
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Figure 3. 6- 293 T cells transfected with pGFP Oct-4 full length and POU domain.  
 
For the sequence to be transported into the nuclei, it needs to have the NLS, for mouse 
this sequence is RKRKR. Only mOct4, has this sequence, while all the other Oct-4 
homologues only have RKRK. Despite this, all the Oct-4 was found in the nuclei. Once 
the POU domain was transported into the nuclei, we can say that the NLS is localized in 
this domain, and that RKRK, is highly likely to represent their NLS.  
 
 
 
Results 
42 
 
3.7.  Luciferase Assay 
 
Transcription factors (TFs) domain architecture includes at least a DNA- binding 
domain (DBD), responsible for binding to a special promoter region, in order for the 
gene be expressed. To see when the transactivator is being expressed, it needs to be 
attached to a reporter gene, in this case luciferase.  
Reporter genes had been used to analyse the function of genetic elements, such as 
promoters and enhances. To assess how Oct-4 full length and the different domains 
function as transactivators, were used used special promoters fused to luciferase gene 
(6Wtkluc, and Gal4lux reporters). These promoters have multiple copies of the 
enhancer element where the TF binds. Binding in this region results in the expression of 
firefly luciferase, an enzyme that can be quantified, giving information about the 
transactivation activity for each gene. 
There can be a lot of variability during the experimental procedures: differences in cell 
seeding numbers, transfection efficiency. Therefore, it is not very accurate to rely only 
on the measurement of the luciferase enzyme. The dual-luciferase assay overcomes this 
problem by using two luciferase reporters, one as the experimental reporter (6Wtkluc 
and Gal4lux) and another as the normal control (Renilla RL-TK). Both the firefly and 
Renilla luciferase proteins have proven to be highly effective as gene reporters. 
The transactivation activity was measured in two different systems, in HeLa and in 
HEK 293T cells, and in ES cells. The transfection in ES cells was not successful and 
therefore there is not the possibility to study the transactivation capacity in this cell 
system. 
 
3.7.1.  pATG 
 
The transactivation of the Oct-4 full length was measured by a Oct-4 binding site 
promoter, that has 6 copies of oligonucleotides with octamer-binding motif from 
mOct4, also known as 6Wtkluc reporter. This plasmid has a transcriptional regulatory 
element that only requires Oct-4 to be active in ES cells (16) 
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Figure 3. 7- pATG-Oct-4 Full length transactivation in HeLa and HEK 293T cells. 
 
Figure 3.7 shows that the different Oct-4 full lengths have different behaviour 
depending on the cell-type. In HeLa cells, all full lengths active 6Wtk-luc with 
exception of Xl60. Axolotl Oct-4 is able to activate the reporter in HeLa cells but 
inhibits it in 293T cells the same happens to sturgeon, but this last one with higher 
activation in 293 T cells then axOct4. Mouse Oct-4, and Xl91 has transactivation 
function in both cell types, but it has higher activity in 293T cells. Zebrafish Pou2 has 
high activity function in HeLa than in 293T cells. 
In HeLa cells the Oct-4 with higher transactivation activity is stOct4, while in 293T 
cells is mOct4. 
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3.7.2.  pDBD 
 
The DBD of the pDBD and the POU domain are very similar, both with DNA-binding 
function, and both able to bind to the reporter promoter (Gal4). To test which domain 
function has a better transactivation function, the Oct-4 full length and domains where 
fused to DBD. 
 
A ) Full length Oct-4 activation 
 
 
Figure 3. 8- pDBD- OCT-4 full lenght activation in HeLa and HEK  293 T cells 
 
As it is possible to visualize (Figure 3. 8) that all the Oct-4 full lengths were able to 
activate Gal4-lux in HeLa cells but not in 293T cells. The only transactivator able to 
binds to Gal4-lux in 293 T cells is mOct4. Axolotl pDBD-FL is the one with higher 
transactivation in HeLa cells than any other species. Mouse Oct-4 has activity in both 
cell types, but has higher expression in HeLa cells than in 293T cells.   
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B)  POU-C constructs 
 
 
Figure 3. 9- pDBD-POU-C Oct-4 transactivation in HeLa and HEK  293T cells 
 
The different Oct-4 DBD-POU-C all have transactivation function in HeLa cells, but 
not in 293T cells. Axolotl Oct-4 is the one with lower transcription activity in HeLa 
while Xl91 was the one with the highest activity, followed by Xl60. 
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 C) N-POU 
 
 
Figure 3. 10- pDBD- N-POU Oct-4 transactivation in HeLa and HEK  293T cells. 
 
According to Figure 3. 10 the species involved in this assay are all active in HeLa cells, 
where mouse is the one with higher transactivation capacity, followed by Xl60. In 293T 
cells only mouse and zebrafish are active, and once again with mouse being the one 
with higher activity. Mouse Oct-4 transactivation activity is better in HeLa cells than in 
293 T cells.  
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 D) N-terminal 
 
 
Figure 3. 11- pDBD-N transactivation in HeLa and HEK 293T cells. 
 
According to Figure 3. 11 the transactivator domain (N) was able to activate Gal4-Lux 
in HeLa cells, and in 293T cells, to exception of axN. 
Sturgeon, Xl91, Xl60 are more active in HeLa than in 293 T cells, the opposite to mN 
that has a higher transactivation function in 293 T than in HeLa cells. 
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E) POU 
 
 
Figure 3. 12- pDBD-POU transactivation in HeLa and in HEK  293 T cells 
 
According to Figure 3. 12, POU inhibits the activity in HeLa cells, but activates Gal4-
lux in 293T cells. axPOU is the transactivator domain with higher activity in 293T cells.  
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F) C-terminal 
 
 
 
Figure 3. 13- pDBD-C transactivation in HeLa and in HEK  293T cells. 
 
According to Figure 3. 13, axolotl, sturgeon and Xl91 able to activate Gal4-lux in HeLa 
cells, while in 293 T cells only axolotl and sturgeon have transactivation capacity. Xl 
91-(C) in 293 T cells is not active, while in HeLa cells is the one with higher 
transactivation function. 
Discussion 
50 
 
Chapter 4. Discussion 
 
Stem cells have great potential for future medicine, due to their abilities to regenerate 
tissues, i.e. pluripotency. However, the mechanisms that regulate stem cell potency is 
largely unknown. Oct-4 protein has attracted a lot of attention as a key regulator for 
stem cell potency and differentiation [16, 21, 24]. Oct-4 has proven to be one of the key 
genes necessary for reprogramming somatic cells into pluripotency. Therefore it is 
important to know which homologue, Oct-4 protein functions better in somatic cells. 
Oct-4 belongs to the octamer-binding (Oct) family of transcription factors, which 
contain the POU domain [40]. Brehm et al. in 1997 proved that in somatic cells the 
individual domains did not have transactivation capacity, only their simultaneous 
presence resulted in Oct-4 activation [20]. In 2002 Niwa et al. demonstrated that the 
same occurs in ES cells, and that the POU domain of Oct-4 plus the N- or C-terminal 
were required for maintaining the ES phenotype [16].The present study was aimed to 
clarify the contribution of the different functional domains for Oct-4 transactivation 
capacity, and how this function is conserved in other species.  
The findings demonstrate that Oct-4 full length and its domains have distinct activities 
in HeLa and in HEK 293T cells, and that in general Oct-4 mutants show similar activity 
function. 
 
4.1. Amino Acid Composition 
 
The amino acid composition determines the functionality of a protein; therefore it is 
important to know if the differences in their activation function are due to differences in 
its general amino acid composition. It is not yet possible to explain all the functions of a 
protein by its amino acid sequence, but it is possible to establish a correlation between 
the structure and the function by its amino acids [41]. 
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According to the amino acid composition of (N) there are two amino acids that are more 
present; Serines and Prolines. It is possible to notice a division between the species 
according these two amino acids, Xl60 and Xl91 have similar enrichment for Proline 
followed by Serine; this similarity is shared by stOct4, when comparing the serine 
amounts.  
In mouse, it has previously been shown that a Proline-rich region in the (N) influences 
transactivation activity function [16]. If we predict the function of the (N) simply by 
comparing the enrichment of prolines, the (N) domain that would have the greatest 
activity would be in the order: mOct4>Xl25>zfpou2>Xl60>stOct4>Xl9>AxOct4. To 
assess this hypothesis the transcriptional activation mediated only by the (N) domain 
was analysed. Data displayed in Fig 3.11 for DBD-N, showed that for the N-domain; 
Xl91>Xl60 and stOct4, suggesting that this simple hypothesis that proline content 
directly reflect transcriptional activity is not correct. However, prolines are not the only 
residue enriched in the mOct4 N-domain. I analysed the sequence for the second most 
enriched amino acid, which was the Serine residues. If Serine richness was a better 
indicator of transcriptional activity of the (N) domain then Xl91>Xl60>stO4 in terms of 
transcriptional activation. Data in Fig 3.11 confirms this hypothesis which indicates that 
not only Proline residues have an important role in activity but also that Serine may 
promote transactivation mediated by the N-domain.  
In the POU domain the amino acid constitution is very similar as this is one of the most 
conserved domains in proteins generally. Even though it is possible to differentiate 
them, all Xenopus homologues are similar with Xl25 sharing the highest similarity with 
Xl91 rather than with Xl60. Zfpou2 and stOct4 share higher similarity, followed by the 
mOct4 and AxOct4.  
Even though all proteins containing POU domains share very high amino acid 
conservation, and all Oct4 homologues have highly conserved (N) and POU domains 
they have clearly have different molecular function. These differences will be 
attributable to specific residue differences between homologues which will require 
further investigation and will alter transactivation activity by affecting interaction with 
other co-factors. 
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The (C) domain amino acid sequence is not as conserved as the (N) and POU domains. 
The amino acid make-up of the (C) domain in some homologues have high amounts of 
proline, and glycine. As for the hypotheses above for the N-domain proline enrichment 
in the (C) might influence transactivation activity function. If this is true, then by 
comparing the enrichment of proline in the (C) domain, then the greatest activity would 
be: zfpou2≈ Xl91> Xl60> Xl91>axOct4>mOct4. To assess this hypothesis the 
transcriptional activation mediated only by the (C) domain was analysed. The data 
displayed in fig. 3.12 for the DBD-C, shows that this hypothesis is not correct  Once the 
(C) domain has been  suggested previously to be regulated by phosphorylation [20, 23] 
on serine, threonine and tyrosine residues [38]. I analysed the sequence for this amino 
acid enrichment. The amino acids are differently distributed by the (C), but these data 
set does not give all the information.More tests to establish a possible relation between 
amino acid and protein function would require a new assay with all the species. 
 
4.2. SEB (Serine [S]/ Glutamic acid [E]) box 
 
Within this study I determined a highly conserved motif in the very N-terminal of the N 
domain which I termed the SEB (Serine [S]/ Glutamic acid [E] box). This is not the 
only region on the (N), mouse has a proline region responsible for increasing the 
transactivation activity [16]. The other (N) domains do not have this proline-rich region, 
instead they have a SEB box. As was mentioned earlier, according to the proline 
function and amino acid percentage, serine might have an important role in the 
transactivation function. Serine and Glutamic acid are chemically similar, a glutamic 
acid when phosphorylated becomes very similar to serine. Mouse (N) domain has serine 
where the other species have glutamic acid. This might indicate that the other species 
can be regulated by phosphorylation. To assess this hypothesis I analysed the 
transcriptional activation mediated only by the (N) in the two cell types. The data 
displayed ( Fig. 3.11), showed a different regulation in HeLa and in 293T cells, in HeLa 
all the (N) are active, while in 293T only mouse (N) has activity. These differences in 
transactivation support the hypothesis that apart from mouse (N), the remaining species 
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are phophosregulated by different co-factors existent in the cell-type. Further tests 
would be required to assess this hypothesis. 
 
4.3. Nuclear Localization 
 
For the Oct-4 be transcribed it needs to be transported to the nuclei, this transportation 
is mediated by a nuclear localization signal (NLS). There are two major groups of NLS 
[42]. The first contain 3-5 amino acids with Lys-Arg/Lys-X-Arg/Lys. The other is a 
bipartite type, containing two clusters of basic regions of 3-4 residues, each separated 
by approximately 10 amino acids [42]. Pan et al. identify the sequence: RKRKR as 
being the Oct-4 NLS for mouse [24].This NLS corresponds to the first type of NLS, 
indicating that mouse Oct-4 does not require two different sequences to be transported 
into the nuclei. This sequence is not found in the other species nevertheless it was found 
a similar sequence: RKRK in the POU domain, in the same conserved region that 
mouse. The pGFP assay showed that the POU domain was the one responsible for the 
transport into the nuclei. Due to the high degree of similarity, it is likely that this 
sequence (RKRK) corresponds to the NLS for the remaining species. In order to test 
this hypothesis more assays would be required sing additional constructs. 
 
4.4. Luciferase Assay 
 
Brehm in 1997 did a similar study by analysing transcriptional activation by the Oct-4 
(N) and (C) domains in their native protein, using a 6W-37tkCAT reporter and with 
Oct4 full length and its domains linked to a Gal4 DNA binding domain. According to 
their results, none of the transactivation domains are able to function alone. In HeLa 
cells both mutants (POU-C and N-POU) can stimulate transcription, but not as much 
has the full length Oct-4 protein, indicating that the (N) and (C) domains are required 
for a full transcription [20]. The present study tested this for the Oct-4 homologues 
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protein, but unfortunately it was not possible to analyse the N-POU and the POU-C 
native state, instead the same mutants were linked to Gal4-DBD. 
 
pATG 
Oct-4 acts together with other transcription factors, such as Sox-2 and Nanog; it 
requires this interaction in order to regulate genes during early development [8]. The 
different transcription factors are differently regulated by cofactors such as Fgf-4 (16). 
There are at least five different reporters that can be differently activated by Oct-4 and 
cofactors, such as Fgf-4 which is activated by Oct-4 and Sox-2 and the Rex promoter is 
activated by Oct-4 and Xox1. The reporter used in this study does not require Sox-2 or 
any other cofactor to be activated; 6WTK is upregulated by Oct-4 alone [16].  
The Oct-4 transactivation function was only possible to study for the full length; no 
mutants were analysed for the luciferase assay. When analysing the Oct-4 expression, 
all the species are active in their native state with exception of Xl60 that does not have 
transactivation activity in HeLa cells (Figure 3.7a) but it has in 293T cells (Fig. 3.7b), 
and the opposite happens with axOct4 and with stOct4. The activity measured in 293T 
cells for Xenopus is consistent with previous works, where Oct homologues were 
upregulated until stage 16 cell of Xenopus, which is until 18h and 15 min [43]; 
involving all Oct-4 homologues.  
These different activities in the different cell types might be due to specific cofactor 
interactions differently existed in HeLa and in 293T cells. The different behaviour 
between Xl91 and Xl60 might be due to their different developmental roles. Xenopus 
Oct-4 homologues are expressed in different stages, and that means different cofactor 
interactions. Xl60 is maternally transcribed [43]; Xl25 both maternally and zygotically 
transcribed, and Xl91 is only zigotically transcribed [43]. For instance, Xl25 and Xl60 
interact with β-catenin to prevent the formation of mesoderm, and β-catenin exists in 
HeLa cells. In this example, the maternally transcribed proteins have specific 
interactions, opening the possibility that Xl91 and Xl60 have different cofactors 
interactions in HeLa cells, but the nature of these interactions remains unclear.  
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pDBD 
When analysing the Oct-4 expression, all the species are active in their native state with 
the exception of Xl60 that does not have transactivation activity in HeLa cells (Figure 
3.7a). All the Oct-4s are also able to function when linked to the Gal4 DNA-binding 
domain (DBD) (Figure 3.8a). When comparing the activity levels in Oct-4 in HeLa and 
293T cells in its native state (Figure 3.7) with Oct-4 linked to Gal4-DBD (Figure 3.8), it 
is possible to see in general a decrease of transcriptional activity. The fact that Oct-4 is 
active in 293T cells without DBD (Fig.3.7b) and inactive in its presence, suggests a 
significant regulatory interaction between DBD and with any of the transactivation 
domains of the Oct-4, resulting in the reporter inhibition. 
In HeLa cells, the only Oct-4 homologues where Gal4-DBD increased transcription 
activity were Xl60 and axOct4, suggesting that there is a different interaction between 
the Oct-4 domains and the Gal4-DBD that result in promoter stimulation. In 293T cells 
native axolotl (axFL) and sturgeon (stFL) are not active, but their status does not change 
when linked to the Gal4-DBD. Mouse Oct-4 is the only one with transcriptional activity 
in 293T cells. To know which domain is responsible for the DBD-mFL transactivation 
it is necessary to compare mouse POU-C and N-POU. By looking to figure 3.9b and 
3.10b we can assume that (mN) is the transcription domain responsible for the 
transactivation in 293T cells. It is also possible to see that mNP and stNP have a 
superior transcription activity then their FL and their POU-C mutants, therefore we can 
assume that their N domains interact both with the POU and Gal4-DBD to stimulates 
the Gal4-lux reporter in 293T cells, suggesting that there might exist cofactors in 293T 
that interact with (mN) resulting in its activation 
In HeLa cells the both mutants (POU-C and N-POU) linked to the Gal4-DBD were able 
to stimulate transcription, but the presence of an alternative DNA binding domain 
presenting opposite results to Brehm study [20]. The separation of transcription 
domains (N) and (C) resulted in a higher activation of the Gal4-lux reporter, them their 
full lenghts. mPC is the only mutant which activity is inferior in POU-C them in N-
POU, but both higher them the full length. Zebrafish-FL and Xl91FL has a similar 
activity to N-POU but both activities are inferior to their respective POU-C mutant 
(figure 3.8a; fig. 3.9a; fig. 3.10a). The presence of an alternative DNA binding domain 
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act as an enhancer when only one of the transcription domains (N) or (C) are present, 
otherwise it acts as a repressor to the Oct-4 transcriptional activation. 
 
Mechanism of C-domain regulation 
POU-C was not able to activate Gal4-lux reporter in 293T cells while in HeLa cells was 
the construct with higher transactivation activity indicating that this mutant, POU-C, is 
cell-type specific. It is known that in mouse, the C-domain is cell-type specific (16) and 
this can explain its different behaviour in HeLa and in 293T cells.  
When the (C) is linked to the DBD, it is active in HeLa but not in 293T cells (Fig. 3.13); 
when (C) is linked to POU and DBD it is also active in HeLa but not in 293T cells; 
when the (C) is removed and only the POU is linked to the DBD, this mutant is inactive 
in HeLa but not in 293T cells. Indicating that the (C) controls (POU) by cell-type 
specific, it is also suggested that differential phosphorylation in HeLa and 293T cells 
can affect transactivation ability of the (C) domain [23]. This can explain the 
transactivation activity that is seen in stOct4, it is the only one active when the (C) is 
linked to DBD in 293T cells (fig. 3.13b). Sturgeon Oct-4 does not have any 
phosphorylation sites in its (C) domains (fig. 3.2) meaning that it requires its native 
DNA binding domain (POU) to mediate cell-type specificity. 
(C) is not the only factor responsible for regulating POU function. It is known that there 
are viral and cellular cofactors that modulate the activity of POU transcription factors. 
These cofactors rather interact with the POU domain than with other transactivation 
domains and that it might result in negative regulation. Consistent with this, is the 
activation of the POU domain only in 293T cells, indicating that in HeLa cells might 
exist different cofactors that does not exist in 293T cells, that interacts with the POU 
domain resulting in negative regulation. 
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(N) domain 
In HeLa cells, both transactivation domains (N) and (C) are sufficient to stimulate Gal4-
lux, whether they are linked to Oct-4 binding domain or to Gal4-DBD, suggesting that 
the two separated transactivation domains have equivalent function in HeLa cells, but 
its activity decrease in the simultaneous presence of Oct-4 and Gal4 DNA binding 
domain, suggesting that (C) and (N) interact in a similar way with DBD and POU. 
 As was said before, the (C) domain is cell-type specific, but the (N) domain does not 
exhibit the same regulation. (N) is active in HeLa and in 293T cells independent if it is 
linked to Oct-4 or Gal4 binding domain. The activities of the two transactivation 
domains can be differentially affected by protein-protein interaction, consistent with 
their different amino acid constitutions. The (C) is a serine/threonine-rich 
transactivation domain [16] while the (N) domain is a proline-rich transactivation 
domain, and its proline region has proved to be essential for transactivation. This region 
is not only responsible for transactivation; ubiquination post-translation modifications 
have also been reported to regulate Oct-4 transcriptional activity [23]. 
Oct-4 is a target of small ubiquitin-related modifier (SUMO) modification that increases 
Oct-4 stability; its DNA binding, and transactivation function. There are three possible 
sumoylation sites, two of them are on the POU domain, and one in the (N) domain. It 
was already proved, that in mouse the sumoylation occurs in the (N) on Lys118. For 
sumoylation occur it needs SUMO-1, E1-activating enzyme; E2-conjungating enzyme 
and E3 ligase [23]. The E3 ligase binds the target protein and provides specificity. Four 
SUMO homologues have been described in mammals one of them, SUMO-1, shares a 
sequence identity with ubiquitin [23] and both ubiquitin and various E3 ligases are 
highly expressed in HeLa cells [44]; another one, SUMO-2 is expressed mainly in the 
kidneys; 293T are human embryonic kidney cells, and therefore may express SUMO-2. 
The sumoylation takes place at a specific target sequence in the substrate protein. The 
consensus SUMO acceptor site requires a strong hydrophobic amino acid; followed by 
the lysine (K), then any amino acid, and finally a glutamic acid (E) or a aspartic acid 
[41]. mOct4 has the SUMO motif 117VKLE120. Analysing the different Oct-4 
homologues, it was possible to find similar motifs conserved in stOct4 (125IKTE128); in 
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zbpou2 (131VKTE134) and in Xl91 (92LKRE95). Xl60 and Xl25 have similar motifs but 
not in the same region as the previous ones. Xl60 has 49IKSE52 and Xl25 has 44LKSE47; 
axOct4 does not have this motif in the (N) were the sumoylation can occurs. These 
events can explain the different activities exhibited for the multiple (N) domains. This 
sumoylation sites can be found in fig.4.1.  
The other two sumoylation sites found in mOct4, 214CKSE217 and 243LKCPK247 (23) can 
be found in the POU domain and surprising, given the relatively high degree of 
conservation of this domain, they are not as conserved as the previous one. A similar 
sequence to the second sumoylation site, can only be found is stOct4 (314YKIE317) and 
in zbpou2 (332YKIE335). The third sumoylation site can be found in axOct-4 
(294LKCPK298); stOct4 (345IKCPK349) and zbpou2 (364VKCPK367). This sumoylation 
sites can be found in Fig. 4.1. 
 
 
Figure 4. 1- Sumoylation sites in Oct-4 homologues (red). 
 
In HeLa cells it is possible to find two substrates that promote sumoylation, SUMO-1 
and E3, while in 293T cells there is the SUMO-2. It is curious to see that all the mutants 
that have the first sumoylation site (DBD-N)  are all active in HeLa and in 293T cells 
(fig. 3.11), and that the mutants (DBD-N-POU) without sumoylation sites in the POU 
domain (Xl91, and Xl60) were not active in 293T cells (fig. 3.9b). It might be necessary 
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for an interaction of the SUMO-2 with POU domain sumoylation sites. Consistent with 
this, is the activation in 293T cells by the POU domain, of the species that have these 
sumoylation sites (fig. 3.12b). SUMO-2 might bind with the POU domain, resulting in 
its transactivation activity, where it requires the simultaneous presence of the second 
and the third sumoylation for stimulating the reporter. This affinity might explain the 
different activities of the POU domain in HeLa and in 293T cells. It also explains the 
lack of activity of axN in 293T cells (fig. 3.11 b), which does not have a POU domain 
thus, the SUMO-2 it is not able to interact with the mutant resulting in its insufficient 
capacity to bind to Gal4-Lux. 
In the presence of two transactivation domains (N and POU), sumoylation might only 
happen in the (N), and that the SUMO-1 and E3, might have more affinity with the (N) 
them with the POU. This can explain both activation results that the mutants with (N) 
are active in HeLa (fig.3.10a and fig.3.11a), and once (N) is removed their lose activity 
capacity in HeLa cells (fig. 3.12a).  
 
4.5. Functional Conservation 
 
Despite it not being possible to complete  the different assays to all the mutants, it was 
still possible to study the transactivation capacity of Oct-4 domains. It is clear that all 
species exhibit different transactivation behaviours in HeLa and in 293T cells, therefore 
their transactivation conservation were individually studied for the different cell types. 
In HeLa cell, the different species of Oct-4 have their transactivation function 
conserved, with exception of Xl60 Oct-4 (fig. 3.7a). In 293T cells, axOct4 and stOct4 
were not able to activate the 6Wtk reporter, while all the others did; meaning that 
despite axOct4 and stOct4 conserved their transactivation function in HeLa cells that 
conservation is lost in 293T cells, the opposite happed to Xl60. The small difference 
between Xl60 and Xl91 is enough to give different transactivations activities; this can 
be somehow related to their different expression stages during Xenopus development.  
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When the same constructs are linked to Gal4 DNA binding domain (DBD), all the 
species are active in HeLa meaning that they share similar mechanism of interaction 
with DBD. Despite differences in activation levels, the different mutants all behave the 
same way in HeLa cells, meaning that their transactivation mechanisms and interactions 
are conserved in this cell type.  
The same does not happen in 293T cells, when the Oct-4 full length is linked to DBD 
only mOct4 mutant is able to activate the reporter; with this it is possible to see that the 
different interactions that might exist in 293T cells are only conserved in the other 
species. The only visible transactivation function that was conserved in all species is 
their POU domains, this is consistent with the fact that this domain is the most 
conserved during evolution. According to the amino acid conservation, the (N) domain 
is more conserved then the (C) domain. When analysing the DND-N it is possible to see 
a similar transactivation activity between the different species with exception of axN. 
The DBD-C assay did not include many species, and therefore is not accurate assuming 
that the functionality, or lack of it, might be conserved. 
In DBD-N-POU the regulation mechanisms and the interaction with DBD are only 
conserved in mOct4 and in stOct4, being the only ones able to stimulate the Gal4-lux 
reporter. In DBD-POU-C mutants, the transactivation function is conserved in all 
species where none of the mutants were able to activate the reporter.  
The POU domain despite their functional conservation, exhibit different transcriptional 
levels some of them very superior to mPOU. The fact that one mutant has more 
transactivation capacity them another is not a good indicator that one species works 
better than other. In ES cells, it is the precise level of Oct-4 that maintains ES cells in 
their pluripotent stage [16]. Insufficient or excessive transcriptional levels of Oct-4 
promote mesoderm formation [16]. Some of the mutants had high transactivation levels, 
such as axPOU, that had 3.5 fold activity in 293T cells; and Xl91C that had 11 fold 
activity whereas axC that had 5 fold both in HeLa cells. For the mutants with (N) or (C) 
and POU plus DBD, the different transactivation levels also diverge. In HeLa cells, for 
N-POU mutants, mOct4 is the one with higher activity, followed by Xl60; while for 
POU-C, the mutant with higher activity level is Xl91>Xl60. 
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Their transactivation function and its levels are not the only aspects necessary to choose 
an alternative study system. There are evolutionary divergences that may account for 
distinct patterns. What  might seem a small difference might have a big impact on the 
embryo development, problems such as severe defect on the axis formation, head 
structures and neural fold happen with some mutations on Xl25 and Xl60 [9]. Despite 
Xl91 and Xl60 have transactivation function, it is required the overexpression of all the 
Oct factors present in Xenopus to generate the same phenotype as mOct-4 [9]. Axolotls 
only have one Oct protein that shares the higher similarity with the mouse than any 
other species, it is already known that its POU domain can rescue ES cells self-renewal, 
but it is not know its effects when its phenotype is knockdown, or if they can replace 
mouse Oct-4 and develop a viable clone. 
Now that it is known the different transactivation capacities for each species, it would 
be necessary to do more assays in order to suggest an alternative model system to study 
pluripotency regulation. It would be necessary to test with the different mutants in their 
ability to rescue ES cell self-renewal, and their effects on reprogramming somatic cells. 
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Chapter 5: Conclusions 
 
This study represents the first investigation of Oct-4 protein domains in lower 
vertebrates by functional expression analyses. Although previous studies have been 
carried out by over-expression in Xenopus and zebrafish, recently other Oct-4 
homologues have been cloned in sturgeon and axolotl, and no functional conservation 
assays have been done to assess their activity until this study. Different approaches were 
employed in order to study Oct4 conversation and to understand function of the 
different domains in regulating activity. 
The amino acid analyses are a useful way to begin to relate amino acid conservation to 
function and transactivation capacity. By comparing sequence analyses and oct4 
functional assay data I concluded that the N-terminal domain represents a 
transcriptional activation domain in Oct4 and that within this domain it is likely that 
proline and serine residues have important roles on increasing transactivation and 
promoting the activation of the luciferase reporters and endogenously Oct4 target genes. 
There are two distinct regions where these two amino acids can be found, in mOct4 
there is the proline region whereas in the remaining species there is a serine-rich region, 
that I termed here as the SEB box. 
It is presumed that all Oct4 homologues would be localised to the nucleus subcellularly 
as this is where transcription factors undertake their role regulating DNA. However this 
has not been proven for all homologues. mOct4 is localised to the nucleus and requires 
an NLS sequence in the POU domain for this localisation. It was not determined 
whether this NLS is present in Oct4 proteins from the lower vertebrates species, or if 
the POU or NLS in these drove this localisation. Here I showed that all Oct4 proteins 
analysed fused to GFP are nuclear and the POU domain at least is responsible for 
transporting Oct-4 into the nuclei. It was possible to highlight a similar NLS sequence 
to the mOct4 (RKRKR) in the POU of all sequences analysed (24). Due to the high 
level of similarity between these sequences and mOct4 NLS there is a strong possibility 
that this sequence is an NLS . 
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The function for the different Oct4 proteins was tested experimentally. One of the aims 
was to study function in the native state of the protein in pluripotent cells, but 
unfortunately due to lack of time, was only possible to study the activity in somatic 
cells. In HeLa cells, only Xl60 was not able to stimulate 6Wtk reporter, meaning that 
the transactivation function was conserved to the remaining proteins. In HeLa and 293T 
cells, the species that had a more similar behaviour to mOct4 was Xl91. 
The construction of different mutants lacking N, POU or C domains linked to Gal4-
DNA binding domain was used as a novel approach to identify the function of specific 
domains and such analyses have not been carried out for Oct4 until this study activating 
a heterologous target. Whenever DBD and two domains are present, the transactivation 
levels are inferior than when in individual domains where employed. (C) and (N) 
domains interact in a similar way with POU and DBD, but in the presence of DBD, they 
present lower activity levels, nevertheless DBD-POU-C has in general more 
transactivation capacity them DBD-N-POU, suggesting that the C-terminal represent a 
more potent transcriptional activator. Furthermore the domain with more transactivation 
capacity when linked to DBD is the (C) domain. The different behaviour exhibited by 
the mutants in HeLa and in 293T cells will be due to differences in regulation and the 
interaction of different cofactors in the cells and will need further study to define these 
differences. 
From previous studies it has been shown that the (C)-domain interacts with the DNA 
binding domain, POU or DBD by differential phosphorylation in HeLa and in 293T 
cells, resulting in the report activation or inactivation depending on the cell-type. The 
phosphorylation sites are in general conserved in the different Oct4 proteins, with the 
notable exception of stOct4 which is the only homologue without predicted 
phosphorylation sites, and therefore this is an explanation for its non-cell-type specific 
function, being the only C-domain active in both HeLa and in 293T cells. 
With exception of mM, the remaining species might be phosphoregulated by the SEB 
box, in the different cell-type. mOct4 through modification of the (N) and POU domains 
has been shown to be regulated by sumoylation and possibly ubiquitination regulating 
protein stability. There are three sumoylation sites in mOct-4, one in the (N) domain 
and two in the POU domain. My analyses of the putative sumoylation sites in the 
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homologues show them to be differently conserved, with the only homologues sharing 
the three sites being mOct4, StO4 and zfPou2. Xl91 and Xl60 only have the putative 
sumoylation site in the (N); and AxOct4 only has the third putative sumoylation site in 
the POU domain. These sumoylation sites are regulated by different cofactors, and it 
has been shown to be cell-type specific.  
Even though there are small differences between Oct4 homologues in their activity to 
transactivate target genes in HeLa and 293T cells, their activity is on conserved. In 
HeLa cells all the mutants had a similar behaviour, meaning that the transactivation 
capacity and regulatory mechanisms of each domain are similar. However the Oct4 
homologues behave differently in 293T cells where axOct4 and stOct4 have a different 
transactivation activity to the others. 
This study also intended to present an alternative method to study Oct4 function which 
it achieved, but the assays displayed here for transactivation function are not enough to 
definitively prove which Oct4 homologue has activity in vivo or to rescue ES self-
renewal, or reprogramming somatic cells which are other published assays for Oct4 
functionality. What is possible to see from my data is that Oct4 from lower vertebrate 
shares a similar functional activity to mammalian Oct4 proteins. According to the 
results, Xenopus is the lower vertebrate that has a similar transactivation activity to 
mouse, more specific: Oct91 protein. This result is consistent with previous studies 
were Xl91 had the capacity to maintain murine ES cells in the absence of Oct-4 [16], 
revelling their high homologue function. But in terms of interactions and developmental 
function, Xenopus does not replace and behave the same way was mouse Oct-4, where 
in order to maintain the same mouse phenotype it is necessary to overexpress all 
Xenopus Oct proteins, Xl91, Xl60 and Xl25 [16]. Not only amphibians are simpler 
species that share all this functional conservation, but they also are easier to 
manipulation and have less ethic regulations.  
The amphibians in this study were Xenopus and axolotl, and axolotl only has one Oct 
protein whereas Xenopus have three; axolotl also have higher similarity mouse than 
with any other species, due to these reasons I was expecting that axolotl would be the 
species to share the highest functional conservation to mammals, but unfortunately it 
was not possible to test the functional activity to all axolotl mutants. By these reason, it 
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would require a more deepl study in axolotl function and I believe that this species 
promises to be the next species where pluripotent mechanisms are going to be study, 
and that axolotl Oct-4 might even be possible to reprogram somatic cells with the same 
efficiency than mouse Oct-4. 
 
5.1. Future work 
 
• It is necessary to redo the luciferase assay with all the different mutants created, 
and study their regulation without the DBD; 
• Study SEB box function, by its ablation; 
• Determine the hypothesis for the nuclear localization site for the lower 
vertebrates; that RKRK represents NLS for Oct-4 homologues; 
• Link the clones to a Myc-tag for future protein measurement; 
• Test the reprogramming capacity for all the mutants with the other three 
transcription factors (Sox-2, c-Myc, and Klf-4); 
• Produce a viable chimeric by replacing mOct-4 for axOct-4, study effects on the 
development; 
• Combine domains between species and study their activity; 
• Study the capacity that the mutants have to maintain ES cells phenotype.  
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APPENDICES 
 
APPENDIX 1 Ambystoma mexicanum 
 
Axolotl Oct4 (accession number AY54376) 
ATGGCTGGGCATTTGGGACAGGAGATTGGGCGGGCTGCCTATGGGTTCGGTGCACAGGC
CTTGCACCTGGGGGCCGGGGGCCTCGAGGCGGGCGGGCCGGGCTTCCTGTCCGAGAGCT
ATGGGCCCTACGCCGGCTTCAAGGCGCTGGAGTATGCCCATGGCGGGGCGGAAGGAGAG
GGCCGACCGGGGGCCCATGGGCTGGCACGGGCCTGGTACCCCTTCTCGGAGGCCTGGGG
CCCTGTGTATGGGCAGAGCGGTGCCGGCGCAGGGTTCGAGAGCAGCCGGGTGGAGGTCA
AGGTGGAGAGGCCCGACAAGGAGGCTGGCTACGGGCAGCAGCACCAGCAGGCCTGGGCT
GGCTACTTCGTGCCCCAGCTGGCAGTGCCCGCCAGGTCGCCTGCGTCCGTGGCCAGCGG
AGGGCAAGTACCGGCCGCACCTGCCAGCCCGTCCGATGACAGCCCGCACAGCAGCACCG
CCAGCAGCAGCAGCGCCAGCCCGGACCTGGGGGCTGGGGGCGCCCCGCGGGACCTGGAC
AGCGGAGACGAGGAAGGGGGGACGTCGGCGGACCTTGAACAGTTTGCCAAGGAGCTGAA
GCAGAAGCGCATCACGCTGGGCTTTACGCAGGCGGATGTAGGGCTGGCGCTCGGGGCGC
TGTACGGGAAGATGTTCAGCCAGACGACGATCTGCCGGTTCGAGGCCCTGCAACTGAGC
TTCAAGAACATGTGTAAACTGAGACCCCTGCTCCAGCGCTGGCTGGTCGAGGCCGACAC
CAACGAGAACCTGCAGGAGCTCTGCAACCTGGAGAATGCCCTGCAACAAGCCCGGAAGA
GGAAAAGAACCAGCATCGAGAACAGCGTCAAGGACAACCTGGAGGCCTTCTTCCTGAAG
TGTCCGAAGCCCACCCATCAGGAGATCGCCCACATCTCCGAGGACCTCAATCTGGAGAA
GGACGTGGTCCGCGTCTGGTTCTGCAACAGGCGACAGAAGGGGAAGCGCAGCATTTGCC
GGGAGGAGTATGATGGCTTCCAGCAGTACCCAGGGATGCAGCCGGGCCCACCGGCTCTG
AGCCACCTGCCCACCTCCTACATCGCGCAGGGCTACAACGGCGCCGCCGCCGCCTTCGC
CGCGGTCTACATGCAGCCCTTCCACGACAGCGAGATGTACTCGCAGACCGTGAGCAGGC
ACCTGCACTCCAACTGA 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
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APPENDIX 2 Mus musculus  
 
Mouse Oct-4 (accession number NM_013633) 
ATGGCTGGACACCTGGCTTCAGACTTCGCCTTCTCACCCCCACCAGGTGGGGGTGATGG
GTCAGCAGGGCTGGAGCCGGGCTGGGTGGATCCTCGAACCTGGCTAAGCTTCCAAGGGC
CTCCAGGTGGGCCTGGAATCGGACCAGGCTCAGAGGTATTGGGGATCTCCCCATGTCCG
CCCGCATACGAGTTCTGCGGAGGGATGGCATACTGTGGACCTCAGGTTGGACTGGGCCT
AGTCCCCCAAGTTGGCGTGGAGACTTTGCAGCCTGAGGGCCAGGCAGGAGCACGAGTGG
AAAGCAACTCAGAGGGAACCTCCTCTGAGCCCTGTGCCGACCGCCCCAATGCCGTGAAG
TTGGAGAAGGTGGAACCAACTCCCGAGGAGTCCCAGGACATGAAAGCCCTGCAGAAGGA
GCTAGAACAGTTTGCCAAGCTGCTGAAGCAGAAGAGGATCACCTTGGGGTACACCCAGG
CCGACGTGGGGCTCACCCTGGGCGTTCTCTTTGGAAAGGTGTTCAGCCAGACCACCATC
TGTCGCTTCGAGGCCTTGCAGCTCAGCCTTAAGAACATGTGTAAGCTGCGGCCCCTGCT
GGAGAAGTGGGTGGAGGAAGCCGACAACAATGAGAACCTTCAGGAGATATGCAAATCGG
AGACCCTGGTGCAGGCCCGGAAGAGAAAGCGAACTAGCATTGAGAACCGTGTGAGGTGG
AGTCTGGAGACCATGTTTCTGAAGTGCCCGAAGCCCTCCCTACAGCAGATCACTCACAT
CGCCAATCAGCTTGGGCTAGAGAAGGATGTGGTTCGAGTATGGTTCTGTAACCGGCGCC
AGAAGGGCAAAAGATCAAGTATTGAGTATTCCCAACGAGAAGAGTATGAGGCTACACAC
CTTTCCCAGGGGGGGCTGTATCCTTTCCTCTGCCCCCAGGTCCCCACTTTGGCACCCCA
GGCTATGGAAGCCCCCACTTCACCACACTCTACTCAGTCCCTTTTCCTGAGGGCGAGGC
CTTTCCCTCTGTTCCCGTCACTGCTCTGGGCTCTCCCATGCATTCAAACTGAGGCACCA
GCCCTCCCTGGGGATGCTGTGAGCCAAGGCAAGGGAGGTAGACAAGAGAACCTGGAGCT
TTGGGGTTAA 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
 
Appendices 
74 
 
APPENDIX 3 Acipenser oxyrinchus oxyrinchus 
 
Sturgeon Oct-4 (not published) 
ATGTCTGATCGGTCTGTCACCCCGGGTTCGGAGGCTTCCAGTCGGGCACACGAGCTCCA
CCGGACGATGTACACGCAGGAGAGCCTAGCCGCTTCTCTTCAGTTCGCCAACGGGATGC
TACAAGACCCGAACTCCGTGTTCAATAAACCCGCCTGCTACAACGGTATCGCCGCCCAA
CATTTCTTCCCGTTTTCTGCAGTCGGCGGTGACTATCGACATCCCGATATTCAGGTAGC
GGACCTGAGCCAAGCTAGACACTGGTACCCNTTCTCTACCCCGGAGCTCACGGGCCAAG
TAGCGGGACTGACCACAGCCCACCAACCGGCGAATCTGAGCCCACGCATCGCAGAAACC
CGGGATCAGACCAAAAGCGACATTAAAACCGAAAAACTGGACGAATTCTCGCNTGAAAG
AAAATCAGCGCTGCCACCGCCGCCCGCTACCATGGCCCCCGGGGTTTATCACTCAAACC
ACTGGAACCCTTCGTTCTGGCCCGGCTTGACCCACGCCCCAGCCCCCGCCGCCACTCCG
GTCTCCTCTTCGCCCAGTAGCCACAGTTACCCGACGGCTGGTGTCTTCACGACGGCAGC
GCCCCAAACGCTACTGGTCCCAGTGCAACAGACCTCGAACCCCGGGAGCAGCGGCTCCT
CCAGTGGCGCGGGCAGTGAAGTGGGGCAGTCTAGCGACTCGGAAGAAGAGGAGAATTTG
TCCACGGAGGAGCTGGAGCAGTTTGCCAAGGAACTGAAACACAAGCGGATCACCCTGGG
ATTCACGCAGGCTGATGTGGGGCTGGCGCTGGGCAACCTCTACGGGAAGATGTTCAGTC
AGACCACGATCTGCCGGTTCGAAGCTCTGCAGCTGAGCTTCAAGAACATGTGCAAGCTG
AAGCCACTGCTGCAACGCTGGCTGAACGAGGCTGAGAACACAGACAACCCGCAGGATAT
GTATAAGATTGAGCGTGTGTTTGCTGACGCCCGGAAGAGGAAGCGCAGGACCAGCCTGG
AGGTGACCGTGCGCGGCGCTCTCGAGTCCTACTTCATCAAGTGCCCGAAGCCCAACACC
CAGGACATCACGCAGATCGCAGAGGACCTCCGCCTGGAGAAAGATGTGGTGCGGGTGCG
GTTCTGTAATCGACGTCAGAAGGGGAAGCGTCTGGCCCTGCCCTTTGATGAGGAGGGTG
CAGAGGGGCAGTATTTCGATCCCAGCCCACAAATGCCCCTGTGCAACGGGCATCTCCAA
ACTCAGGGGTACCCTGGCACTGCACCCCCACACCTCTACCTACCCGCCTTCCACAAGCC
AGAGGTCTTCAAGCAGACCCTGCCCCAGGGATTCCCTGTGGGGCTGGGACACCTGACCA
GCTAG 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
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APPENDIX 4 Danio rerio 
 
Zebrafish Oct4 (accession number NM_131112) 
ATGACGGAGAGAGCGCAGAGCCCAACAGCAGCAGACTGCAGACCCTATGAGGTCAACAG
GGCCATGTATCCTCAAGCCGCGGGCCTGGATGGACTTGGCGGAGCGTCCTTGCAGTTTG
CGCACGGTATGCTTCAGGATCCAAGTCTGATTTTTAACAAGGCCCATTTCAACGGAATC
ACCCCCGCGACAGCCCAGACCTTCTTTCCATTTTCAGGCGATTTTAAAACGAACGATTT
GCAAGGTGGCGACTTTACGCAGCCCAAACACTGGTACCCGTTTGCGGCCCCCGAGTTCA
CTGGGCAGGTTGCAGGAGCGACGGCCGCCACTCAGCCGGCGAACATCAGCCCTCCTATC
GGCGAGACTAGAGAGCAAATTAAGATGCCATCTGAGGTCAAAACCGAGAAAGATGTTGA
AGAATACGGGAATGAAGAAAACAAGCCGCCGTCACAATATCACCTCACCGCTGGAACAT
CTTCCGTCCCCACCGGGGTGAACTACTACACGCCATGGAACCCTAATTTCTGGCCTGGA
CTGTCCCAAATTACGGCCCAAGCTAATATTTCCCAAGCTCCCCCAACTCCCTCCGCTTC
ATCCCCATCTCTGTCTCCGTCTCCCCCTGGAAATGGGTTCGGAAGCCCAGGATTTTTTA
GCGGAGGCACCGCGCAAAACATTCCCTCAGCTCAAGCGCAAAGTGCACCCCGGAGCAGT
GGGTCCTCCAGTGGAGGATGCAGTGATTCTGAGGAAGAGGAGACTCTGACTACTGAAGA
TTTGGAGCAGTTTGCGAAAGAGCTTAAACACAAGCGCATCACTCTGGGCTTCACGCAGG
CAGATGTGGGACTCGCGCTTGGAAACTTGTATGGCAAAATGTTCAGTCAGACGACAATC
TGCCGCTTTGAGGCTCTCCAACTTAGTTTCAAGAACATGTGCAAACTGAAGCCGTTGTT
GCAGAGGTGGTTGAACGAGGCCGAAAACTCCGAGAACCCTCAGGATATGTACAAAATTG
AACGGGTGTTTGTCGACACGCGAAAAAGAAAACGAAGGACCAGCTTGGAAGGCACAGTC
CGTTCTGCTCTAGAGTCGTACTTCGTGAAGTGCCCCAAACCCAACACTCTGGAGATAAC
GCACATATCCGATGATCTAGGCCTGGAGAGAGATGTAGTGCGTGTATGGTTCTGCAACC
GTAGACAGAAGGGAAAGCGTCTAGCTTTGCCCTTTGATGACGAGTGTGTTGAAGCACAG
TATTACGAGCAGAGTCCACCACCTCCACCCCACATGGGTGGCACTGTGCTCCCAGGTCA
AGGCTATCCTGGACCAGCCCATCCTGGAGGAGCCCCTGCCTTATACATGCCATCCCTCC
ACCGACCAGATGTCTTCAAAAACGGCTTGCACCCTGGTTTGGTGGGTCATCTCACCAGCT
AA 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
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APPENDIX 5 Xenopus laevis 
 
Xenopus laevis Oct-91 (Accesion number M60077)  
 
ATGTATAACCAACAGACCTACCCTTCCTTTACCCACAACCCAGCCCTGATGCCAGATGG
CAGCGGACAGTATAACTTGGGCACCTACACCGGCATGGCCAGGCACCCCCACCAAGCTC
AAGCATTCTTTCCTTTCTCTGGGGTGAAATCGGACTATGGGGACCTTGGGGGGCAAACT
ACTAGCGTGGGTGATACTTCTGCCTGGAACCCCCTAACTTCTCTGGATTCTGCCAACCA
GTTGGGCATCTCCGGCCAAGGGAACCCGTTTAAGAACTTAAAAAGGGAGAGAGAAGATG
ATGAGGAGAAATCAGAATCTCCTGAGCCCAAATGCAGCCCACCGTCTCTTCCACCCGCC
TATTACACCCATGCGTGGAATCCCACCACCACCTTCTGGTCTCAGGTCTCCTCAAGTGG
GACCACGGTCGTGTCCAAGCCTTTACCCACCCCACTCCAGCCCGGTGATAAATGTGACC
CCGTGGAGGCAAATAAAATTTTTACCAGTAGCCCCGATAAGTCAGGAGAGAGTGGGATC
TCCAGCTTGGACAACAGTCGCTGTAGCAGCGCCACCAGCAGCTCATCTGGTGGGACCAA
CGTGGGGACCCCTAGAAGCCTTTCCAGGGGAGCTAGTGATGGGCTGAGCAGTGACAGTG
AGGAGGAAGCCCCTAATTCTGGGGAGATGGAGCAGTTTGCCAAGGATCTGAAGCACAAA
CGGATCACAATGGGCTACACTCAGGCGGATGTTGGCTACGCTCTAGGAGTGCTTTTTGG
TAAAACATTCAGCCAGACCACCATCTGCCGATTCGAGTCCCTGCAGCTCTCCTTCAAGA
ACATGTGCAAGCTGAAACCTCTGCTGCGGAGTTGGCTCCATGAGGTTGAAAACAATAAA
AACCTCCAAGAAATCATCAGCCGAGGGCAGATAATTCCTCAGGTTCAGAAGAGAAAGCA
CAGGACCAGCATCGAGAACAACGTGAAATGCACCTTGGAGAACTATTTCATGCAGTGCT
CAAAGCCAAGTGCCCAGGAGATCGCCCAGATTGCGAGAGAGCTGAACATGGAGAAAGAC
GTGGTGAGAGTCTGGTTCTGCAACCGGCGGCAGAAGGGCAAGCGCCAGGTGTACCCCTA
TATTAGGGAGAATGGCGGGGAGCCTTATGACGCCCCCCAAACCTTGACACCCCCTTCTC
AAGGTCCTTTTCCATTACCCCAAGTGATGCCCTCACAAGTTTTTCCCACGGTCCCACTG
GGTGCCAACCCTACGATCTACGTTCCGACGTATCACAAAAACGACATGTTCCCCCAGGC
AATGCATCATGGGATTGGCATGGGTAACCAAGGCAACTAG 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
Appendices 
77 
 
APPENDIX 6 Xenopus laevis- Oct60 
 
Xenopus laevis Oct-60 (accesion number: M60075) 
 
 
ATGGACCAGCCCATATTGTACAGCCAAACCTCCTTCCCCAACTTCACCTACAGCCCAGG
AGTGGTGCAAGACGGGGGCAATTACCAGTATTTGGGCAACTACAATGCCCCGTCCTACC
CGCAGCCGTTCTTCCATGTCCCTGTTATAAAATCAGAATTTGGTGCCCATGAGGAAGAA
ACGCCGGGGAGTTGCCATGCTGCTTCCTTTGACTGGAACCTGTACCCTCACTTTCAGAT
CTCTAACCAGGCGGCTTCCAACAGTTCTGGAGATCCAAGTCCAGAGGGAAGAACTGAGG
AGGATGGTTCTGTCAGTGAAGGGAGGTCCTCCAGTTCCCCTTCCCCCAATTCTCCCCTG
GTGCCTTCCTTTGCCCAATATTGGCATTATCCCTCCTGGCAGCAGGGGAACCTAACCAA
CCAACCTCACACTCTTTTTGATGGGGGTGATGAGAAGCCCCAACAGTCTCGTCACAGTC
CAACGGCCTCGCTAGGGAGTGGGGCGTCCAACACCGAGGATGAGGAGGTCCCCAGTGCC
ATCTCCAGTAGAGCAGAAAGAGGTCTCTGTAGTCCCTCTCCTAATAATGCCTCATGTGG
CCCTGGAACTGAAGAGGATGGAATGACCCTTGAGGAGATGGAAGAGTTTGCCAAGGAGC
TGAAACAGAAGCGGGTGGCACTGGGTTATACCCAAGGAGACATTGGCCACGCCCTGGGA
ATATTATACGGGAAGATGTTCAGCCAGACGACTATCTGCCGCTTTGAGTCCCTGCAACT
GACCTTCAAAAATATGTGTAAACTCAAACCCCTATTGGAGCAGTGGCTGGGAGAGGCGG
AGAATAACGACAACCTACAGGAGATGATCCACAAGGCCCAGATTGAGGAGCAGAACCGC
AAGCGGAAGATGAGGACCTGCTTTGATACTGTTCTAAAGGGCCAACTAGAGGGCCACTT
CATGTGCAATCAGAAACCTGGTGCCAGGGAGCTGACGGAAATTGCCAAAGAACTGAGTC
TGGAGAAAGATGTGGTGAGGGTCTGGTTCTGCAACCGGCGGCAGAAGGAGAAGAGCAAG
TTCAGAATGTCCAAGGGGCATGAGTTTGTGGGTGGTGCCAGTCCTGGATCCATCCAATC
AGAACACATTTCTTTCACCCCCATTCCAGCTAATTCCCAGGACTATGGATTGGCCTCTC
TACACCCCAACCGAGCCCCCTTCTACCCACCTCCCTTCCCCAGGAATGAGCTGTTCCCT
CACATGGCTCCGGGGATATCTATGGGGGTCCTGACCGGCTGA 
 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
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APPENDIX 7- Xenopus laevis- Oct25 
 
Xenopus laevis Oct-25 (Accesion number M60074) 
 
ATGTACAGCCAACAGCCCTTCCCAGCCTTCGCTTTCAACGCCGGACTCATGCAGGATCC
CGCCAACTGTCATTTTGGGGGTTACGCGGGTTTAGGACACCCCCAGCCCTTCTCCTTCG
CCTTCTCTACGCTGAAATCGGAAAACGGAGAGTCTGGAGTTCAGGGTATGGGGGACTGT
ACGACTCCTGTGATGCCCTGGAACTCACTGGCGTGTTTCGATCACCAGGTCCAGATGGA
GAACAACCAGCAAGGGAATCCGCCCAGAGCCCCAAGTCCGACTCTCAGCGACTCCAGGA
TTAAGGTCAAAGAGGAGGTTGTCCATGAAACTGACAGCGGAGAAGAGTCCCCAGAACCC
AAATACCCCAGCCCCCCTAATCCCTCTCTCTACTACCCCAACGCATGGACTGGCGCCCC
TTTCTGGCAAGTGAACCCCACGCCGGGCAATAACATCAACCCAATGCCCAACCAGACTC
TTGTGAAAAACACCAGCCTACCGGGGAACACCACCTACCCCACCCCAGCAAACCAAAGC
CCCAATACCCCAGTAGACTGTGTGACCTCCAGTATGGAAAGCAGCAGATGCAGCAGCAC
CAACTCCCCCAATGGGGCAATTAATGAACGGGCCACCACTATCCCTAATGGAGAGATGC
TTGATGGGGGGCAATCCAGCGACAATGAGGAGGAGGTTCCCAGCGAATCAGAAATGGAG
CAGTTTGCCAAAGATCTGAAGCACAAGCGAGTGTCCCTGGGCTACACACAGGCGGATGT
TGGCTACGCACTCGGGGTCCTGTATGGCAAGATGTTCAGTCAGACGACAATCTGTCGCT
TCGAGTCGCTGCAGCTCAGCTTCAAGAACATGTGTCAACTGAAACCTTTCCTGGAGCGC
TGGGTGGTGGAGGCAGAGAACAACGACAACCTGCAGGAGTTGATCAACCGGGAGCAGGT
CATTGCCCAAACACGGAAGAGAAAAAGGAGGACGAACATAGAGAATATAGTGAAGGGGA
CCCTGGAGAGTTACTTCATGAAATGTCCCAAGCCGGGCGCCCAGGAGATGGTGCAGATC
GCCAAGGAACTGAACATGGACAAAGATGTGGTCCGGGTCTGGTTTTGCAATCGGCGGCA
GAAAGGCAAGCGCCAGGGAATGCCCACCGTTGAGGAGAACGACGGCGAAGGCTACGATG
TTGCACAGACCATGGGTCGCCCTGTTGGACACTATGCGCTGCAGCAGGTGGTGACCCCA
CAAGGTTACATGGCAGCTCCGCAGATTTACGCCTCGGCGGGCCACAAAAACGACCTGTT
CCCCCAGACGGTCCCACACGGAATGGCCATGGGGGGCCACATTGGCTGA 
 
White background: N domain 
Light gray: POU domain 
Dark gray: C domain 
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APPENDIX 8. Primers combination 
 
List of the combination of the primers for al fragments and their respective fragment 
sizes 
 
Specie Primer Domain Size (bp) 
Axolotl Oct4 Nhe1 F+ HindIII R Full- Lenght 1197 
 Age1 F+ HindIII R POU-C 648 
 Nhe1 F+ Sal1 R N-POU 996 
 Nhe1+ Age1 R N domain 549 
 Age1 F+ Xho1 R POU domain 447 
 Xho1 F+ HindIIIR C domain 201 
    
Mouse Oct4 Nhe1 F+ BglII R Full Length 1131 
 Age1 F+ HindIII R POU-C 732 
 Nhe1 F+ Xho1 R N-POU 846 
 Nhe1+ Age1 R N domain 399 
 Age1 F+ Xho1 R POU domain 447 
 Xho1 F+ HindIIIR C domain 285 
    
Sturgeon Oct4 Nhe1 F+ HindIII R Full Length 1362 
 Age1 F+ HindIII R POU-C 657 
 Nhe1 F+ Sal1 R N-POU 1158 
 Nhe1F + Age1 R N domain 705 
 Age1 F+ Sal1 R POU domain 453 
 Xho1 F+ HindIIIR C domain 204 
    
Zebrafish Nhe1 F+ HindIII R Full Lenght 1419 
 Age1 F+ HindIII R POU-C 663 
 Nhe1 F+ Xho1 R N-POU 1209 
 Nhe1+ Age1 R N domain 756 
 Age1 F+ Xho1 R POU domain 453 
 Xho1 F+ HindIIIR C domain 210 
    
Xenopus 91 Nhe1 F+ HindIII R Full length 1338 
 Age1 F+ HindIII R POU-C 678 
 Nhe1 F+ Xho1 R N_POU 1143 
 Nhe1+ Age1 R N domain 660 
 Age1 F+ Xho1 R POU domain 483 
 Xho1 F+ HindIIIR C domain 195 
    
Xenopus 60 Nhe1 F+ HindIII R Full length 1281 
 Age1 F+ HindIII R POU-C 669 
 Nhe1 F+ Xho1 R N-POU 1076 
 Nhe1+ Age1 R N domain 612 
 Age1 F+ Xho1 R POU domain 464 
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 Xho1 F+ HindIIIR C domain 205 
    
Xenopus 25 Nhe1 F+ HindIII R Full length 1347 
 Age1 F+ HindIII R POU-C 657 
 Nhe1 F+ Xho1 R N-POU 1140 
 Nhe1+ Age1 R N domain 690 
 Age1 F+ Xho1 R POU domain 450 
 Xho1 F+ HindIIIR C domain 207 
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APPENDIX  9. Amino acid composition of Oct-4 N terminal 
 
Axolotl Mouse Sturgeon Zebrafish Xl 91 Xl 60 Xl 25 
Amino Acid Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % 
Alanine 31 16.94 10 7.52 26 11.06 27 10.71 12 5.45 12 5.88 13 5.65 
Cysteine 0 0 4 3.01 1 0.43 2 0.79 3 1.36 3 1.47 5 2.17 
Aspartic Acid 7 3.83 5 3.76 9 3.83 8 3.17 13 5.91 9 4.41 8 3.48 
Glutamic Acid 13 7.1 12 9.02 13 5.53 15 5.95 11 5 15 7.35 15 6.52 
Phenylaline 6 3.28 4 3.01 9 3.83 14 5.56 7 3.18 9 4.41 9 3.91 
Glycine 34 18.58 23 17.29 15 6.38 25 9.92 21 9.55 19 9.31 18 7.83 
Histidine 6 3.28 1 0.75 10 4.26 4 1.59 4 1.82 7 3.43 4 1.74 
Isoleucine 1 0.55 2 1.5 4 1.7 8 3.17 3 1.36 4 1.96 4 1.74 
Lysine 3 1.64 3 2.26 5 2.13 7 2.78 9 4.09 2 0.98 5 2.17 
Leucine 10 5.46 8 6.02 13 5.53 10 3.97 13 5.91 8 3.92 9 3.91 
Methionine 1 0.55 3 2.26 4 1.7 4 1.59 3 1.36 1 0.49 8 3.48 
Asparagine 0 0 2 1.5 9 3.83 13 5.16 11 5 13 6.37 23 10 
Proline 15 8.2 19 14.29 23 9.79 29 11.51 21 9.55 23 11.27 31 13.48 
Glutamine 9 4.92 6 4.51 13 5.53 17 6.75 10 4.55 12 6.37 13 5.65 
Arginine 7 3.83 3 2.26 8 3.4 5 1.98 6 2.73 15 2.45 4 1.74 
Serine 20 10.93 11 8.27 33 14.04 28 11.11 37 16.82 33 16.18 24 10.43 
Threonine 1 0.55 4 3.01 18 7.66 20 7.94 19 8.64 9 4.41 17 7.39 
Valine 8 4.37 9 6.77 11 4.68 6 2.38 7 3.18 7 3.43 11 4.78 
Tryptophan 38 1.64 2 1.5 3 1.28 3 1.19 3 1.36 3 1.47 3 1.3 
Tyrosine 8 4.37 2 1.5 6 2.55 7 2.78 7 3.18 9 4.41 6 2.61 
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APPENDIX  10. Amino acid composition of Oct-4 POU domain 
 
Axolotl Mouse Sturgeon Zebrafish Xl 91 Xl 60 Xl 25 
Amino Acid Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % Nº  Mol % 
Alanine 11 7.38 7 4.7 10 6.62 7 4.64 6 3.97 7 4.55 7 4.67 
Cysteine 5 3.36 5 3.36 4 2.65 4 2.65 5 3.31 5 3.25 4 2.67 
Aspartic Acid 6 4.03 3 2.01 7 4.64 7 4.64 3 1.99 4 2.6 5 3.33 
Glutamic Acid 12 8.05 12 8.05 12 7.95 12 7.95 11 7.28 18 11.69 13 8.67 
Phenylaline 8 5.37 6 4.03 8 5.3 8 5.3 7 4.64 8 5.19 7 4.67 
Glycine 6 4.03 6 4.03 6 3.97 7 4.64 7 4.64 9 5.84 8 5.33 
Histidine 2 1.34 1 0.67 1 0.66 2 1.32 3 1.99 3 1.95 1 0.67 
Isoleucine 5 3.36 6 4.03 6 3.97 5 3.31 9 5.96 6 3.9 6 4 
Lysine 14 9.4 16 10.74 15 9.93 14 9.27 15 9.93 17 11.04 15 10 
Leucine 20 13.42 21 14.09 18 11.92 19 12.58 12 7.95 17 11.04 12 8 
Methionine 2 1.34 2 1.34 3 1.99 3 1.99 5 3.31 8 5.19 6 4 
Asparagine 9 6.04 7 4.7 7 4.64 7 4.64 12 6.62 7 4.55 9 6 
Proline 3 2.01 3 2.01 4 2.65 4 2.65 4 2.65 2 1.3 3 2 
Glutamine 11 7.38 12 8.05 9 5.96 7 4.64 13 8.61 11 7.14 12 8 
Arginine 11 7.38 12 8.05 15 9.93 14 9.27 11 7.28 10 6.49 12 8 
Serine 7 4.7 8 5.37 5 3.31 7 4.64 9 5.96 5 3.25 7 4.67 
Threonine 8 5.37 9 6.04 10 6.62 11 7.28 7 4.64 8 5.19 6 4 
Valine 6 4.03 9 6.04 7 4.64 8 5.3 9 5.96 5 3.25 11 7.33 
Tryptophan 2 1.34 3 2.01 1 0.66 2 1.32 2 1.32 2 1.3 2 1.33 
Tyrosine 1 0.67 1 0.67 3 1.99 3 1.99 3 1.99 2 1.3 4 2.67 
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APPENDIX  11. Amino acid composition of Oct-4 C-terminal 
 
 
Axolotl Mouse Sturgeon Zebrafish Xl 91 Xl 60 Xl25 
Amino Acid Nº Mol % Nº Mol % Nº Mol % Nº Mol % Nº Mol % Nº Mol % Nº Mol % 
Alanine 8 11.94 9 9.47 3 4.41 4 5.71 3 4.62 5 7.35 7 10.14 
Cysteine 1 1.49 2 2.11 1 1.47 1 1.43 0 0 0 0 0 0 
Aspartic Acid 2 2.99 1 1.05 2 2.94 3 4.29 2 3.08 1 1.47 3 4.35 
Glutamic Acid 3 4.48 8 8.42 4 5.88 3 4.29 0 0 3 4.41 3 4.35 
Phenylaline 3 4.48 4 4.21 5 7.35 2 2.86 3 4.62 5 7.35 1 1.45 
Glycine 5 7.46 7 7.37 8 11.76 10 14.29 6 9.23 8 11.76 10 14.49 
Histidine 4 5.97 2 2.11 4 5.88 5 7.14 3 4.62 4 5.88 4 5.8 
Isoleucine 2 2.99 2 2.11 0 0 0 0 2 3.06 4 5.88 2 2.9 
Lysine 0 0.00 1 1.05 2 2.94 1 1.43 1 1.54 0 0 1 1.45 
Leucine 3 4.48 13 13.68 8 11.76 6 8.57 3 4.62 4 5.88 2 2.9 
Methionine 3 4.48 1 1.05 1 1.47 2 2.86 4 6.15 2 2.94 5 7.25 
Asparagine 2 2.99 1 1.05 1 1.47 1 1.43 4 6.15 3 4.41 2 2.9 
Proline 6 8.96 12 12.63 11 16.18 14 20 13 20 11 16.18 6 8.7 
Glutamine 6 8.96 8 8.42 6 8.82 3 4.29 6 9.23 2 2.94 6 8.7 
Arginine 2 2.99 4 4.24 0 0 1 1.43 0 0 2 2.94 1 1.45 
Serine 6 8.96 7 7.37 2 2.94 3 4.29 2 3.08 7 10.29 1 1.45 
Threonine 2 2.99 5 5.26 4 5.88 2 2.86 5 7.69 2 2.94 4 5.8 
Valine 2 2.99 2 2.11 2 2.94 4 5.71 4 6.15 2 2.94 6 8.7 
Tryptophan 0 0.00 2 2.11 0 0 0 0 0 0 0 0 0 0 
Tyrosine 6 8.96 3 3.16 3 4.41 4 5.71 3 4.62 2 2.94 4 5.8 
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APPENDIX 12. pGEM®-T Easy vector (Promega, UK) 
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APPENDIX 13. p6Wtk-luc vector 
 
 
 
